METHODS TO DETECT HK2 POLYPEPTIDES

Abstract: Diagnostic methods employing antibodies which bind to prostate antigen phk2 or hk2 and which do not significantly react with prostate specific antigen hk3. Use in diagnosis of prostate cancer.

Description: METHODS TO DETECT HK2 POLYPEPTIDES Background of the Invention The glandular kallikreins are a subgroup of serine proteases which are involved in the post-translational processing of specific polypeptide precursors to their biologically active forms. In humans, three members of this family have been identified, and some of their properties characterized (Clements, Endoc. Rev.. 10, 343 (1989); Clements, Mol. Cell Endo.. 99, 1 (1994); Jones et al., Acta Endoc. 127. 481 (1992)). The hKLKl gene encodes the tissue kallikrein protein, hKl, the hKLK2 gene encodes the prostate-specific glandular kallikrein protein, hK2, and the hKLK3 gene encodes the prostate-specific antigen protein, hK3 (PSA). Northern blot analysis of mRNA shows that both hK2 and PSA are expressed mainly in the human prostate, while expression of hKl is found in the pancreas, submandibular gland, kidney, and other nonprostate tissues (Chapdelaine et al., FEBS Lett.. 236. 205 (1 88); Young et al., Biochem. 31, 818 (1992)). The nucleotide sequence homology between the exons of hKLK2 and hKLK3 is 80%, whereas the nucleotide sequence homology between the exons of hKLK2 and hKLKl is 65%. The deduced amino acid sequence homology of hK2 to PSA is 78%, whereas the deduced amino acid sequence homology of hK2 to hKl is 57%. Moreover, the deduced amino acid sequence of hK2 suggests that hK2 may be a trypsin-like protease, whereas PSA is a chymotrypsin-like protease. PSA levels are widely used as a prognostic indicator of prostate carcinoma. However, since the concentration of PSA in serum is elevated in patients with either prostatic cancer (PCa) or benign prostatic hyperplasia (BPH), the detection of elevated levels of PSA does not distinguish between these diseases. Moreover, the high degree of homology of hK2 to PSA raises some question as to the specificity of antibodies currently used to detect the levels of PSA. If the levels of circulating hK2 are unrelated to pCa or BPH, then antibodies raised to preparations of PSA which are contaminated with hK2, or to regions of PSA with homology hK2, can result in false positive results. However, determination of the levels of hK2 in serum, and the correlation of those levels in patients with pCa or BPH, have not been accomplished. Thus, a need exists for improved methods and reagents for the diagnosis of pCa, BHP or related conditions. Summary of the Invention The invention provides a diagnostic method comprising contacting an amount of purified antibodies which specifically bind to phK2 or hK2 with a sample of physiological fluid obtained from a human. The physiological fluid comprises hK2 or phK2. The antibodies are contacted with the sample for a sufficient time to allow the formation of binary complexes between at least a portion of said antibodies and a portion of phK2 or hK2, wherein said antibodies do not significantly react with hK3. The presence of one or both of said complexes in said sample is then detected, and the amount thereof is correlated to the presence or absence of prostate cancer. The amount of one or both of said complexes can be compared to a standard amount that is representative, for example, of the amount of one or both complexes in a control sample of the same fluid from a human not at risk of, or afflicted with, prostate cancer. Likewise, the amount can be compared to a standard amount that represents a cut-off, above which or below which further evaluation for prostate cancer is carried out, and below which or above which, respectively, the human is likely to be cancer-free. This assay is based on the discovery that phK2 is detected in the supernatant of a prostate carcinoma cell line and that hK2 is present in human physiological fluid from prostate cancer patients. Thus, this method is useful for monitoring the treatment and/or progression of prostate cancer, or for the early detection of prostate cancer. As used herein, a human "at risk of prostate cancer is a male who has benign prostatic hyperplasia (BPH) or high grade prostatic intraepithelial neoplasia, or a male whose male family members, e.g., a brother, father, uncle or grandfather, have or had benign prostatic hyperplasia, high grade prostatic intraepithelial neoplasia or prostate cancer (PCa). PSA (hK3) forms covalently-linked complexes with anti-chymotrypsin (ACT) and alpha 2-macroglobulin (MG) in human serum (Leinonen et al., Clin. Chem.. 34, 2098 (1993)). Monitoring the ratios of different forms of PSA (complexed versus uncomplexed) in serum has been useful in differentiating between BPH and pCa (Christensson et al., J. Urol.. 150. 100 (1993)). The results presented hereinbelow show that hK2 polypeptides also form complexes with ACT and MG. Complex formation of hK2 with ACT was unexpected since hK2 is a trypsin-like protease and ACT is typically an inhibitor of chymotrypsin-like proteases. However, it suggests that hK2 bears conformational/structural similarities with PSA (hK3) which dictate its reactivity with inhibitors. hK2 complexed with ACT and MG along with free (unbound) hK2 would thus be expected to represent the major immunologically detectable or measurable components of hK2 in human serum. The results presented hereinbelow also show that hK2 complexes can be detected in the sera of prostatic cancer patients. Therefore, monitoring for the presence and/or amount of hK2 complexes may also be important in distinguishing between PCa and BPH. Thus, the invention also provides a diagnostic method comprising determining the amount of hK2 polypeptide which is bound to plasma protein from a sample of human physiological fluid and correlating the amount of said bound hK2 polypeptide to the presence or absence of prostate cancer in said human. A preferred embodiment of the invention is a diagnostic method in which the amount of bound hK2 polypeptide is determined relative to a value representative of said amount of bound hK2 in a human not at risk of, or afflicted with, prostate cancer. Another preferred embodiment of the invention is a diagnostic method comprising separating from a sample of human physiological fluid hK2 polypeptide which is bound to plasma protein from hK2 polypeptide which is not bound to plasma protein prior to determining the amount of bound hK2 polypeptide. Methodologies for the separation of proteins of differing molecular weights and/or conformations is well known to the art. Further provided is a method to detect hK2 complex formation with plasma proteins. The method comprises determining the amount of hK2 polypeptide which is bound to plasma protein relative to the amount of hK2 polypeptide which is not bound to plasma protein. Alternatively, the amount of hK2 polypeptide which is bound to plasma protein relative to the total hK2 polypeptide (bound plus unbound) is determined. The invention further provides a method for detecting or determining unbound hK2 polypeptide in a sample of a human physiological fluid containing hK2. The method comprises contacting an amount of purified antibodies which specifically bind to hK2 with the sample to be tested for a sufficient time to allow the formation of binary complexes between at least a portion of said antibodies and a portion of said hK2. The antibodies do not significantly react with hK3 and do not significantly react with hK2 which is bound to a plasma protein. A preferred embodiment of the invention includes attaching said antibodies to a solid surface prior to contacting the antibodies with the sample to be tested. Also provided is a purified antibody that specifically binds an hK2 polypeptide and does not bind hK3, wherein the antibody also binds to hK2 which is bound to a plasma protein. The invention further provides a diagnostic kit for detecting or determining phK2 or hK2. The kit comprises packaging, containing, separately packaged (a) a solid phase which binds a capture antibody; and (b) a known amount of a detection antibody, wherein the detection antibody specifically binds to phK2 or to hK2 and not to hK3. Another embodiment of the invention is a diagnostic kit for detecting or determining phK2. The kit comprises packaging, containing, separately packaged (a) a solid phase which binds a capture antibody; and (b) a known amount of a detection antibody, wherein the detection antibody specifically binds the pro form of hK2 and not hK3 or hK2. Yet another embodiment of the invention is a diagnostic kit for detecting or determining phK2 or hK2. The kit comprises packaging, containing, separately packaged (a) a solid phase which binds a capture antibody; and (b) a known amount of the capture antibody, wherein the capture antibody specifically binds to phK2 or to hK2 and not to hK3. Also provided is a method of detecting hK2 in vitro. The method comprises contacting a sample, such as a fluid sample, comprising an amount of an hK2 polypeptide with an amount of a peptide substrate for a sufficient time to allow cleavage of the peptide substrate by the hK2 polypeptide to yield subunits of the peptide, wherein the peptide substrate comprises contiguous amino acid residues which form a site to which an hK2 polypeptide binds. Then the presence or amount of the subunits of the peptide substrate is determined. Preferably, the peptide substrate is a synthetic peptide. Brief Description of the Figures Figure 1 depicts the amino acid sequences of wild type mature hK2 (SEQ ID NO: l) and hK3 (SEQ ID NO:7). Figure 2 depicts the amino acid sequence, and corresponding nucleic acid sequence, of wild type pphK2 (SEQ ID NO:5 and SEQ ID NO:6, respectively), phK2 (SEQ ID NO:3 and SEQ ID NO:4) and hK2 (SEQ ID NO:l and SEQ ID NO:2). Codon 217 (GCT, Ala) is shown in bold and underlined. Figure 3 is a schematic diagram of the pGT expression vectors pGThK2 and pGThK_2 v2 ' 7 . Figure 4 depicts chromatographic profiles from the purification of phK2 v217 . (A) A DEAE chromatogram of 7 day spent medium from AV12 cells transfected with a vector encoding pphK2 v217 . A sample of the spent medium was applied in bicarbonate buffer, pH 8 and eluted with a salt gradient. The A 280 elution profile is represented by a solid line. The dotted line represents the results of an ELISA assay of a portion of individual column fractions which was dried onto microtiter plates and developed with a rabbit anti-pphK2 antibody. (B) The hydrophobic interaction profile of pooled DEAE fractions. Fractions 24 to 30 from the DEAE chromatographic eluates of (A) were pooled, concentrated and applied to an HIC (hydrophobic interaction column) column in 1.2 M sodium sulfate, and eluted with a decreasing salt gradient. The elution profile (A 28 o) is represented by a solid line. The dotted line represents the results of an ELISA assay of a portion of individual column fractions which was dried onto microtiter plates and developed with a rabbit anti-hK2 antibody. (C) hK2- containing fractions from the 22 minute peak from (B) were concentrated and applied to a Pharmacia S12 size exclusion column. Fractions were collected and analyzed by SDS/PAGE. The 19.4 minute peak appeared homogeneous by SDS-PAGE. Figure 5 represents an SDS/PAGE analysis of purified hK2 and PSA. A 1.5 mg sample of purified phK2 v217 or PSA was boiled in sample buffer with (R) or without (N) 1% beta-mercaptoethanol. Samples were subjected to SDS/PAGE on a 4-20% gel. The protein bands were visualized by staining the gel with silver. Figure 6 depicts Conconavalin A staining of phK2 v217 . The predicted position of phK2 is designated by an arrow. ZCE (an anti-CEA mAb) and BSA were included as examples of glycosylated and non-glycosylated proteins, respectively. The presence of a band at the predicted position in the phK2 lane demonstrates that this protein is glycosylated. Figure 7 represents the conversion of pro to mature hK2 v21? by trypsin cleavage. Trypsin (1% w/w) was incubated with phK2 v217 for 10 minutes at 37°C in 100 mM borate buffer pH 8, and then subjected to HIC-HPLC. The dashed line represents the profile of the phK2 v217 prior to incubation with trypsin. The solid line represents the profile of phK2 after trypsin digestion. The profiles have been superimposed for comparison. The identity of the two forms was confirmed by N-terminal sequencing of the protein. Figure 8 depicts Western blot analysis of seminal fluid using monoclonal antibody (mAb) hKlG 586.1. Processed seminal fluid was diluted 1 :1 in PBS and centrifuged at 10,000 X g for 20 minutes. The supernatant was subjected to SDS/PAGE on a 8-25% gel using the PhastSystem (Pharmacia). Protein was transferred to nitrocellulose and incubated with protein-G purified HKlG 586.1 (1 μg/ml) followed by goat anti-mouse IgG-HRP (1 : 1000). The blot was developed using the ECL detection system (Amersham). Figure 9 represents a time course study of hK2 expression in AVI 2 celis. AV12-hK2 clone #27 was grown to -60-70% confluency, then cells were washed with HBSS and serum free HH4 media was added. Spent medium was withdrawn each day, concentrated and subjected to SDS/PAGE on a 12% gel. Proteins were electroblotted and probed with monoclonal antibody HK1D 106.4, which detects both phK2 and hK2 (1 : 1000) or HKlG 464.3, which detects phK2 (1 :1000), followed by goat anti-mouse IgG-HRP (1:500). The blot was developed with ECL (Amersham) according to the manufacturer's instructions. Purified phK2 v2,? and hK2 v217 were used as controls. The position of hK2 is indicated by the arrow. Figure 10 represents a time course study of expression of the variant form of hK2 in transfected AV12 cells. At -60-70% confluency, AV12-hK2 v2 ' 7 cells were washed with HBSS and serum free HH4 media was added. Spent media was withdrawn each day, concentrated and subjected to SDS/PAGE on a 12% gel. Proteins were electroblotted and probed with monoclonal antibodies HK1D 106.4 and HKlG 464.3. Goat anti-mouse IgG-HRP (1 :500) was used as a secondary antibody and the blot was developed with ECL (Amersham) according to the manufacturer's instructions. Purified phK2 v2,? and hK2 v217 were used as controls. The position of hK2 is indicated by the arrow. Figure 1 1 is a plot of hK2 expression and cell viability over time. AVI 2- hK2 clone #27 was grown to 60-70% confluency, washed with HBSS and serum free HH4 media was added. Spent media was withdrawn each day and the hK2 concentration was measured by ELISA using HKl D 106.4 or HKl G 464.3 as a primary antibody, and goat anti-mouse IgG-HRP as a secondary antibody. The reaction was developed with OPD (Sigma, St. Louis, MO). Viable cells were enumerated daily using trypan blue dye exclusion. Figure 12 depicts the expression of hK2 in PC3 and DU145 cells. PC3 and DU145 cells transfected with pGThK2 were grown to -60-70% confluency, washed and resuspended in serum free HH4 media. The spent medium of pGThK2 transfected DU145 cells was collected 3 days after resuspension and the spent medium of pGThK2 transfected PC3 cells was collected 5 days after resuspension. Spent media were concentrated and subjected to SDS/PAGE on 12% gels. Proteins were electroblotted and probed with HK1D 106.4 or HKlG 464.3 as described above. Purified phK2 v21? and phK2 v217 were used as controls. The position of hK2 is indicated by an arrow. Figure 13 depicts the expression of hK2 by selected hK2-containing AVI 2 clones. Cells from hK2 containing AVI 2 clone numbers 10, 27, 31 and 32 were grown to ~60-70%o confluency and washed with HBSS, then serum free HH4 media was added. Spent media was withdrawn 7 days after the addition of serum free media, concentrated and subjected to SDS/PAGE on a 12% gel. Proteins were electroblotted and probed with HK1D 106.4 or HKlG 464.3. Goat anti-mouse IgG-HRP (1 :500) was used as a secondary antibody and the blot was developed with ECL (Amersham) according to manufacturer's instructions. Purified phK2 v217 and hK2 v2 ' 7 were used as controls. The position of hK2 is indicated by an arrow. Figure 14 depicts the expression of phK2 v217 in selected AV12-hK2 v217 clones. Cells from AV12 clone numbers 2, 3, 4, 45 and 48 were grown to approximately 60-70% confluency and washed with HBSS, and serum free HH4 media was added. Spent media was withdrawn 7 days after the addition of serum free media, concentrated and subjected to SDS/PAGE on a 12% gel. Proteins were electroblotted and probed with HK1D 106.4 or HKlG 464.3. Goat anti-mouse IgG-HRP (1 :500) was used as a secondary antibody and the blot was developed with ECL (Amersham) according to manufacturer's instructions. Purified phK2 v217 and hK2 v217 were used as controls. The position of hK2 is indicated by an arrow. Figure 15 depicts the amidolytic specificity of hK2 v2π , hK2, and PSA for residues 210-236 of hK2. The synthetic peptide (0.63 mM) was digested overnight at 37°C with 1 μg/ml hK2, 40 μg/ml hK2 v2 ' 7 or 100 μg/ml PSA, and the digestion products separated by RP-HPLC. Peaks were normalized to compare the qualitative aspects of cleavage. Figure 16 depicts the specificity of hK2 and PSA for different peptide substrates. Open arrows denote peptide bonds cleaved by PSA; solid arrows denote bonds cleaved by hK2. Peptide #1 (SEQ ID NO.T6) represents amino acid residues 210-236 of hK2. Peptide #2 (SEQ ID NO:l 8) represents amino acid residues 1-14 of angiotensinogen, i.e., the renin substrate tetradecapeptide. Peptide #3 (SEQ ID NO: 19) represents amino acid residues -7 to +7 of phK2. Peptide #4 (SEQ ID NO:20) represents amino acid residues 41 -56 of hK2. Peptide #5 (SEQ ID NO:21) represents the amino acid sequence of the oxidized beta chain of insulin. Peptide #6 (SEQ ID NO:22) represents amino acid residues 196-213 of PMSA. Figure 17 depicts the activation of phK2 v217 by hK2 but not hK2 v217 . phK2 v217 contains the pro leader peptide sequence VPLIQSR (SEQ ID NO: 12), a sequence not present in hK2 v217 . Panel A shows phK2 v217 incubated with 1% w/w hK2. Panel B is a control with 40% w/w hK2 v217 incubated with phK2 v217 for 6 hours. Figure 18 depicts Western blot analysis of hK2 incubated with protease inhibitors. Each sample was separated on a 8-25% gradient SDS-PAGE, blotted and probed with HKl G586.1. hK2 was incubated for 4 hours at 37°C with the following inhibitors: Lane 1, antichymotrypsin (ACT); lane 2, alpha 2- antiplasmin; lane 3, anti-thrombin III; lane 4, alpha 1 -protease inhibitor (anti- trypsin); lane 5, alpha 2-macroglobulin; lanes 1 and 2 show a covalent complex of the predicted Mr of 90-100 kD. Serpin inhibitors were employed at 20 μM, macroglobulin at 2.8 μM, and hK2 at 0.175 uM. Lane 5 shows the higher Mr complexes representing covalent complex formation of hK2 with alpha 2- macroglobulin. Figure 19 depicts complex formation of hK2 in human serum. Western blots of hK2 and PSA were incubated with human serum. hK2 samples were probed with HK1G586.1 and PSA samples with PSM773 anti-PSA mAb Lanes 1-6 contain hK2 samples and lanes 7 and 8 are PSA samples. Lane 1 represents an hK2 control. Lane 2 contains hK2 incubated with ACT for 4 hours. Lane 3 represents a serum control with no added protease. Lane 4 contains hK2 incubated for 15 minutes with serum. Lane 5 contains hK2 incubated with serum for 4 hours. Lane 6 contains hK2 incubated with purified alpha-2 macroglobulin for 4 hours. Lane 7 contains PSA incubated with serum for 4 hours. Lane 8 contains PSA incubated with purified alpha-2 macroglobulin for 4 hours. Figure 20 depicts a dose response curve for phK2 v2π which employed monoclonal antibody HK1G586 -B- or HKl G464 -•- as the capture reagent and HK1H449 as the detection reagent. Figure 21 depicts a graph of the concentration of hK2 or phK2 in the media of mibolerone-stimulated LNCaP cells over time. Monoclonal antibody HK1G586 -□- or HK1G464 -0- was employed to measure phK2 and hK2 levels, or phK2 levels, respectively. The insert depicts hK2 enzymatic activity in the supernatant of mibolerone-stimulated LNCaP cells. Figure 22 depicts Western blot analysis of supernatant from LNCaP cells with monoclonal antibody HK1G464. Lane 1 contains 75 ng of purified hK2. Lane 2 contains 75 ng of purified phK2. Lane 3 contains 200 ng of purified PSA isolated from seminal fluid. Lane 4 contains 5 μg of pphK2. Lane 5 contains 5 μg of ppPSA. Lanes 6-9 contain spent media of LNCaP cells from days 1 -4 post-mibolerone stimulation. Figure 23 depicts Western blot analysis of supernatant from LNCaP cells with monoclonal antibody HK1G586. Lane 1 contains 75 ng of purified hK2. Lane 2 contains 75 ng of purified phK2. Lane 3 contains 200 ng of purified PSA isolated from seminal fluid. Lane 4 contains 5 μg of pphK2. Lane 5 contains 5 μg of ppPSA. Lanes 6-9 contain spent media of LNCaP cells from days 1 -4 post-mibolerone stimulation. Figure 24 depicts the detection of hK2 in a panel of prostate carcinoma sera. Serum samples from 10 patients were electrophoresed on 4-20% polyacrylamide gels and blotted to nitrocellulose. Each lane contains 10 μg of hK2 enriched human serum from prostate cancer patients. Lane 1 : anti-hK2 mab, HKlG587.1. Lane 2: anti-hK2 mab HK1B 104.1. Lane 3: anti-PSA mab, PSM773. Lane 4: negative control mab. Figure 25 depicts the detection of hK2-ACT complexes in serum from a prostate carcinoma patient by monoclonal antibody HKl G586.1. Lane 1 : mab HK1G586.1. Lane 2: negative control mab. Lane 3: anti-ACT mab, AC1A086. Lane 4: molecular weight markers. Detailed Description of the Invention The high degree of amino acid sequence homology of hK2 to PSA, and the fact that the expression of both hK2 and PSA is essentially limited to the prostate, suggests that measuring the serum concentrations of both proteins can be useful in the diagnosis and monitoring of prostatic cancer (pCa). Recently, pphK2 was expressed in bacteria (Saedi et al., Mol. Cell. Endoc. 109. 237 (1 95)). Bacterially derived pphK2 can be used to generate antibodies to the non-conformationally dependent epitopes on hK2. However, to discern the steps involved in the biosynthesis of hK2 and to obtain antibodies specific for the fully processed and secreted form of hK2, expression of hK2 in mammalian cells is necessary. As used herein, the term "hK2 polypeptide" includes recombinant pre- pro, pro and mature hK2 polypeptides. A mature hK2 polypeptide having the amino acid sequence shown in Figure 1 (SEQ ID NO:l), as well as "variant" polypeptides which share at least 90% homology with SEQ ID NO:l in the regions which are substantially homologous with hK3, i.e., which regions are not identified by bars as shown in Figure 1. Such hK2 polypeptides also possess antigenic function in common with the mature hK2 molecule of Figure 1, in that said polypeptides are also definable by antibodies which bind specifically thereto, but which do not cross-react with hK3 (or hKl). Preferably, said antibodies react with antigenic sites or epitopes that are also present on the mature hK2 molecule of Figure 1. Antibodies useful to define common antigenic function are described in detail in Serial No. 08/096,946, i.e., polyclonal antisera prepared in vivo against hK2 subunit 41-56. "Isolated hK2 nucleic acid" is RNA or DNA containing greater than 15, preferably 20 or more, sequential nucleotide bases that encode a biologically active hK2 polypeptide or a variant fragment thereof, that is complementary to the non-coding strand of the native hK2 polypeptide RNA or DNA, or hybridizes to said RNA or DNA and remains stably bound under stringent conditions. Thus, the RNA or DNA is isolated in that it is free from at least one contaminating nucleic acid with which it is normally associated in the natural source of the nucleic acid and is preferably substantially free of any other mammalian RNA or DNA. The phrase "free from at least one contaminating source nucleic acid with which it is normally associated" includes the case where the nucleic acid is reintroduced into the source or natural cell but is in a different chromosomal location or is otherwise flanked by nucleic acid sequences not normally found in the source cell. An example of isolated hK2 nucleic acid is RNA or DNA that encodes a biologically active hK2 polypeptide sharing at least 90% sequence identity with the hK3 -homologous regions of the hK2 peptide of Figure 1, as described above. The term "isolated, substantially homogenous" as used with respect to an hK2 polypeptide is defined in terms of the methodologies discussed herein below. As used herein, the term "recombinant nucleic acid," i.e.. "recombinant DNA" refers to a nucleic acid, i.e., to DNA that has been derived or isolated from any appropriate tissue source, that may be subsequently chemically altered in vitro, and later introduced into target host cells, such as cells derived from animal, plant, insect, yeast, fungal or bacterial sources. An example of recombinant DNA "derived" from a source, would be a DNA sequence that is identified as a useful fragment encoding hK2, or a fragment or variant thereof, and which is then chemically synthesized in essentially pure form. An example of such DNA "isolated" from a source would be a useful DNA sequence that is excised or removed from said source by chemical means, e.g, by the use of restriction endonucleases, so that it can be further manipulated, e.g., amplified, for use in the invention, by the methodology of genetic engineering. Therefore, "recombinant DNA" includes completely synthetic DNA sequences, semi-synthetic DNA sequences, DNA sequences isolated from biological sources, and DNA sequences derived from introduced RNA, as well as mixtures thereof. Generally, the recombinant DNA sequence is not originally resident in the genome of the host target cell which is the recipient of the DNA, or it is resident in the genome but is not expressed, or not highly expressed. As used herein, "chimeric" means that a vector comprises DNA from at least two different species, or comprises DNA from the same species, which is linked or associated in a manner which does not occur in the "native" or wild type of the species. The recombinant DNA sequence, used for transformation herein, may be circular or linear, double-stranded or single-stranded. Generally, the DNA sequence is in the form of chimeric DNA, such as plasmid DNA, that can also contain coding regions flanked by control sequences which promote the expression of the recombinant DNA present in the resultant cell line. For example, the recombinant DNA may itself comprise a promoter that is active in mammalian cells, or may utilize a promoter already present in the genome that is the transformation target. Such promoters include the CMV promoter, as well as the SV40 late promoter and retroviral LTRs (long terminal repeat elements). Aside from recombinant DNA sequences that serve as transcription units for hK2 or portions thereof, a portion of the recombinant DNA may be untranscribed, serving a regulatory or a structural function. "Control sequences" is defined to mean DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotic cells, for example, include a promoter, and optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers. "Operably linked" is defined to mean that the nucleic acids are placed in a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice. Aside from recombinant DNA sequences that serve as transcription units for hK2 or portions thereof, a portion of the recombinant DNA may be untranscribed, serving a regulatory or a structural function. The recombinant DNA to be introduced into the cells further will generally contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of transformed cells from the population of cells sought to be transformed. Alternatively, the selectable marker may be carried on a separate piece of DNA and used in a co-transformation procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells. Useful selectable markers are well known in the art and include, for example, antibiotic and herbicide-resistance genes, such as neo, hpt, dhfr, bar, aroA, dapA and the like. Reporter genes are used for identifying potentially transformed cells and for evaluating the functionality of regulatory sequences. Reporter genes which encode for easily assayable proteins are well known in the art. In general, a reporter gene is a gene which is not present in or expressed by the recipient organism or tissue and which encodes a protein whose expression is manifested by some easily detectable property, e.g., enzymatic activity. Preferred genes include the chloramphenicol acetyl transferase gene (cat) from Tn9 of E. coli, the beta-glucuronidase gene (gus) of the uidA locus of E. coli, and the luciferase gene from firefly Photinus pyralis. Expression of the reporter gene is assayed at a suitable time after the DNA has been introduced into the recipient cells. Other elements functional in the host cells, such as introns, enhancers, polyadenylation sequences and the like, may also be a part of the recombinant DNA. Such elements may or may not be necessary for the function of the DNA, but may provide improved expression of the DNA by affecting transcription, stability of the mRNA, or the like. Such elements may be included in the DNA as desired to obtain the optimal performance of the transforming DNA in the cell. The general methods for constructing recombinant DNA which can transform target cells are well known to those skilled in the art, and the same compositions and methods of construction may be utilized to produce the DNA useful herein. For example, J. Sambrook et al., Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press (2d ed., 1989), provides suitable methods of construction. The recombinant DNA can be readily introduced into the target cells by transfection with an expression vector comprising cDNA encoding hK2, for example, by the modified calcium phosphate precipitation procedure of C. Chen et al., Mol. Cell. Biol.. 7, 2745 (1987). Transfection can also be accomplished by lipofectin, using commercially available kits, e.g., provided by BRL. Suitable host cells for the expression of hK2 polypeptide are derived from multicellular organisms. Such host cells are capable of complex processing and glycosylation activities. In principle, any higher eukaryotic cell culture can be employed in the practice of the invention, whether from vertebrate or invertebrate culture. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as Spodopterafrugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori have been identified. See, e.g., Luckow et al., Bio/Technologv. 6, 47 (1988); Miller et al., in Genetic Engineering. J. K. Setlow et al., eds., Vol. 8 (Plenum Publishing, 1986), pp. 277-279; and Maeda et al., Nature. 315. 592 (1985). A variety of viral strains for transfection are publicly available, e.g., the L-l variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV, and such viruses may be used, preferably for transfection of Spodopterafrugiperda cells. Recovery or isolation of a given fragment of DNA from a restriction digest can employ separation of the digest on polyacrylamide or agarose gel by electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the gel from DNA. For example, see Lawn et al., Nucleic Acids Res.. 9, 6103 (1981), and Goeddel et al., Nucleic Acids Res.. £, 4057 (1980). "Southern analysis" or "Southern blotting" is a method by which the presence of DNA sequences in a restriction endonuclease digest of DNA or DNA-containing composition is confirmed by hybridization to a known, labeled oligonucleotide or DNA fragment. Southern analysis typically involves electrophoretic separation of DNA digests on agarose gels, denaturation of the DNA after electrophoretic separation, and transfer of the DNA to nitrocellulose, nylon, or another suitable membrane support for analysis with a radiolabeled, biotinylated, or enzyme-labeled probe as described in sections 9.37-9.52 of Sambrook et al., supra. "Northern analysis" or "Northern blotting" is a method used to identify RNA sequences that hybridize to a known probe such as an oligonucleotide, DNA fragment, cDNA or fragment thereof, or RNA fragment. The probe is labeled with a radioisotope such as 32 P, by biotinylation or with an enzyme. The RNA to be analyzed can be usually electrophoretically separated on an agarose or polyacrylamide gel, transferred to nitrocellulose, nylon, or other suitable membrane, and hybridized with the probe, using standard techniques well known in the art such as those described in sections 7.39-7.52 of Sambrook et al.. supra. "Polymerase chain reaction" or "PCR" refers to a procedure or technique in which amounts of a preselected fragment of nucleic acid, RNA and/or DNA, are amplified as described in U.S. Patent No. 4,683,195. Generally, sequence information from the ends of the region of interest or beyond is employed to design oligonucleotide primers. These primers will be identical or similar in sequence to opposite strands of the template to be amplified. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage or plasmid sequences, and the like. See generally Mullis et al., Cold Spring Harbor Symp. Quant. Bio ≤l, 263 (1987); Erlich, ed., PCR Technology. (Stockton Press, NY, 1989). "Stringent conditions" are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M NaCl/0.0015 M sodium citrate (SSC); 0.1% sodium lauryl sulfate (SDS) at 50°C, or (2) employ a denaturing agent such as formamide during hybridization, e.g., 50%o formamide with 0.1%) bovine serum albumin 0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42°C. Another example is use of 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8). 0.1 % sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 μg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC and 0.1% SDS. When hK2 polypeptide is expressed in a recombinant cell other than one of human origin, the hK2 polypeptide is completely free of proteins or polypeptides of human origin. However, it is necessary to purify hK2 polypeptide from recombinant cell proteins or polypeptides to obtain preparations that are substantially homogeneous as to hK2 polypeptide. For example, the culture medium or lysate can be centrifuged to remove particulate cell debris. The membrane and soluble protein fractions are then separated. The hK2 polypeptide may then be purified from the soluble protein fraction and, if necessary, from the membrane fraction of the culture lysate. hK2 polypeptide can then be purified from contaminant soluble proteins and polypeptides by fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on an anion-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; or ligand affinity chromatography. Once isolated from the resulting transgenic host cells, derivatives and variants of the hK2 polypeptide can be readily prepared. For example, amides of the hK2 polypeptides of the present invention may also be prepared by techniques well known in the art for converting a carboxylic acid group or precursor, to an amide. A preferred method for amide formation at the C- terminal carboxyl group is to cleave the polypeptide from a solid support with an appropriate amine, or to cleave in the presence of an alcohol, yielding an ester, followed by aminolysis with the desired amine. Salts of carboxyl groups of the hK2 polypeptide may be prepared in the usual manner by contacting the peptide with one or more equivalents of a desired base such as, for example, a metallic hydroxide base, e.g., sodium hydroxide; a metal carbonate or bicarbonate base such as, for example, sodium carbonate or sodium bicarbonate; or an amine base such as, for example, triethylamine, triethanolamine, and the like. N-acyl derivatives of an amino group of the present polypeptides may be prepared by utilizing an N-acyl protected amino acid for the final condensation, or by acylating a protected or unprotected peptide. O-acyl derivatives may be prepared, for example, by acylation of a free hydroxy peptide or peptide resin. Either acylation may be carried out using standard acylating reagents such as acyl halides, anhydrides, acyl imidazoles, and the like. Both N- and O-acylation may be carried out together, if desired. In addition, the internal hK2 amino acid sequence of Figure 1 can be modified by substituting one or two conservative amino acid substitutions for the positions specified, including substitutions which utilize the D rather than L form. The invention is also directed to variant or modified forms of the hK2 polypeptide. One or more of the residues of this polypeptide can be altered, so long as antigenic function is retained. Conservative amino acid substitutions are preferred—that is, for example, aspartic-glutamic as acidic amino acids; lysine/arginine/histidine as basic amino acids; leucine/isoleucine, methionine/valine, alanine/valine as hydrophobic amino acids; serine/glycine/alanine/threonine as hydrophilic amino acids. Acid addition salts of the polypeptides may be prepared by contacting the polypeptide with one or more equivalents of the desired inorganic or organic acid, such as, for example, hydrochloric acid. Esters of carboxyl groups of the polypeptides may also be prepared by any of the usual methods known in the art. Once isolated, hK2 polypeptide and its antigenically active variants, derivatives and fragments thereof can be used in assays for hK2 in samples derived from biological materials suspected of containing hK2 or anti-hK2 antibodies, as disclosed in detail in Serial No. 08/096,946. For example, the hK2 polypeptide can be labeled with a detectable label, such as via one or more radiolabeled peptidyl residues, and can be used to compete with endogenous hK2 for binding to anti-hK2 antibodies, i.e., as a "capture antigen" to bind to anti-hK2 antibodies in a sample of a physiological fluid, via various competitive immunoassay format for hK2 which uses anti-hK2 antibodies which are capable of immobilization is carried out by: (a) providing an amount of anti-hK2 antibodies which are capable of attachment to a solid surface; (b) mixing a sample of physiological fluid, which comprises hK2, with a known amount of hK2 polypeptide which comprises a detectable label, to produce a mixed sample; (c) contacting said antibodies with said mixed sample for a sufficient time to allow immunological reactions to occur between said antibodies and said hK2 to form an antibody-hK2 complex, and between said antibodies and said labeled polypeptide to form an antibody-labeled polypeptide complex; (d) separating the antibodies which are bound to hK2 and antibodies bound to the labeled polypeptide from the mixed sample; (e) detecting or determining the presence or amount of labeled polypeptide either bound to the antibodies on the solid surface or remaining in the mixed sample; and (f) determining from the result in step (e) the presence or amount of said hK2 in said sample. In another format which can detect endogenous hK2 in a sample by a competitive inhibition immunoassay, a known amount of anti-hK2 antibody is added to a sample containing an unknown amount of endogenous hK2. The known amount is selected to be less than the amount required to complex all of the hK2 suspected to be present, e.g., that would be present in a sample of the same amount of physiological fluid obtained from a patient known to be prostate cancer. Next, a known amount of the hK2 polypeptide of the invention or a subunit thereof, comprising a detectable label is added. If endogenous hK2 is present in the sample, fewer antibodies will be available to bind the labeled hK2 polypeptide, and it will remain free in solution. If no endogenous hK2 is present, the added labeled polypeptide will complex with the added anti-hK2 antibodies to form binary complexes. Next, the binary antibody-antigen complexes are precipitated by an anti-mammal IgG antibody (sheep, goat, mouse, etc.). The amount of radioactivity or other label in the precipitate (a ternary complex) is inversely proportional to the amount of endogenous hK2 that is present in the sample, e.g., a pellet containing reduced amounts of radioactivity is indicative of the presence of endogenous hK2. Alternatively to the conventional techniques for preparing polyclonal antibodies or antisera in laboratory and farm animals, monoclonal antibodies against hK2 polypeptide can be prepared using known hybridoma cell culture techniques. In general, this method involves prepared an antibody-producing fused cell line, e.g., of primary spleen cells fused with a compatible continuous line of myeloma cells, and growing the fused cells either in mass culture or in an animal species from which the myeloma cell line used was derived or is compatible. Such antibodies offer many advantages in comparison to those produced by inoculation of animals, as they are highly specific and sensitive and relatively "pure" immunochemically. Immunologically active fragments of the present antibodies are also within the scope of the present invention, e.g., the f(ab) fragment, as are partially humanized monoclonal antibodies. The invention will be further described by reference to the following detailed examples. Example 1. Materials and Methods Construction of mammalian hK2 expression vectors A cDNA (approximately 820 bp long) encoding the entire prepro-hK2 (pphK2) (from nucleotide #40 to #858 relative to the start site of the pphK2 transcript), as shown in Figure 2, was synthesized from RNA of human BPH tissue using reverse-transcription polymerase chain reaction (RT-PCR) technology with a pair of hK2 specific oligonucleotide primers (5ΑCGCGGATCCAGCATGTGGGACCTGGTTCTCT3' SEQ ID NO:8 and 5 'ACAGCTGCAGTTTACTAGAGGTAGGGGTGGGAC 3 ' SEQ ID NO:9). This cDNA was generated such that 5' and 3' ends (with respect to pphK2 sense sequence) were bracketed with BamHl and Pstl sequences, respectively. The cDNA was then purified by agarose gel electrophoresis, and digested with BamHl and Pstl restriction enzymes. The restricted cDNA was ligated with BamHl-Pstl digested pVL1393 plasmid vector and transformed into the E. coli HB101 strain. E. coli harboring pphK2 cDNA pVL1393 plasmid vector were selected. The pphK2 containing insert was sequenced. Plasmid pphK2 cDNA/pVL1393 was mass-produced in E. coli and purified by CsCl gradient ultra-centrifugation. Plasmid pρhK2/pVL 1393 in E. coli HB 101 has been deposited in the American Type Culture Collection, Rockville, MD, USA on May 2, 1994 under the provisions of the Budapest Treaty and has been assigned accession number ATCC 69614. A 0.8 kb fragment representing the entire pphK2 coding sequence (Figure 2) was generated by PCR using primers A (5 'ATATGGATCCATATGTCAGCATGTGGGACCTGGTTCTCTCC A3 ' ) (SEQ ID NO: 10) and B (5ΑTATGGATCCTCAGGGGTTGGCTGCGATGGT3') (SEQ ID NO:l 1) and plasmid pVL1393 containing pphK2 (gift from Dr. Young, Mayo Clinic) as the template. PCR products were inserted into the TA-cloning vector (Invitrogen Corp., San Diego, CA) and the DNA of the entire insert was sequenced. To obtain the mammalian hK2 expression vectors, the hK2-containing inserts were isolated from the corresponding TA clones and inserted into the Bel 1 site of the plasmid pGT-d (Berg et al., Nucl. Acids Res.. 20, 54-85 (1992)) (gift from Dr. Brian Grinnell, Lilly) under the control of the GBMT promoter. The mammalian expression vectors, PLNS-hK2 and PLNC-hK2 were obtained by cloning the 0.8 kb wild type hK2 insert from the corresponding TA vector into the plasmids, pLNSX and pLNCX (Miller et al., Biotech.. 9, 980 (1989)), respectively. The orientation of the insert in all the mammalian expression vectors was confirmed by DNA sequencing. Generation of recombinant clones AVI 2-664 (ATCC CRL-9595), a cell line derived from adenovirus- induced tumors in Syrian hamster, and DU145 cells were cultured in Dulbecco's modified Eagle's medium (high glucose) supplemented with 10% fetal bovine serum (D10F). PC3 cells were cultured in Minimal Eagle Medium containing 10%) fetal bovine serum. AVI 2 cells were transfected with the hK2 expression vectors using the calcium phosphate method (Maniatis et al., supra (1989)). Three days after transfection cells were resuspended in D10F + 200 nM methotrexate (MTX). Drug-resistant clonal cell lines were isolated after 2-3 weeks and their spent medium was analyzed by Western blots. PC3 and DU145 cells were transfected with hK2 mammalian expression vectors using lipofectamine (Gibco-BRL, Gaithersburg, MD) and clones (PC3-hK2 and DU145-hK2) were selected in media containing 400 μg/ml G418. Purification and sequencing of the protein AV12-hK2 clones were grown in D10F + 200 nM MTX. At about 60% confluency the cells were washed with Hank's balanced salt solution and resuspended in serum-free HH4 medium. The spent medium was collected 7 days after the addition of serum-free spent medium and stored at -20°C. To purify the protein, the serum-free spent medium was concentrated and exchanged into 50 mM sodium bicarbonate pH 8. Samples were filtered with 0.2 μ filters and then pumped directly onto a TSK DEAE-5PW HPLC column, 21 mm X 150 mm, at a flow rate of 5 ml/minute. Buffer A contained 50 mM Na bicarbonate pH 7.9 and Buffer B contained 50 M Na bicarbonate plus 0.5 M NaCl pH 7.6. The elution profile was developed with a gradient from 0-50% Buffer B over 35 minutes; 50-100% B from 35-40 minutes and isocratic elution at 100% B for 5 minutes before re-equilibration in Buffer A. The flow rate was 5 mL/minute throughout. In the above procedure, borate buffer could replace bicarbonate buffer with no noticeable difference. DEAE fractions were assayed for the presence of hK2 by the dried-down ELISA method (see below) using rabbit anti-pphK2 (Saedi et al., Mol. Cell. Endoc. 109. 237 (1995)). Fractions with hK2 activity were pooled and concentrated by ultrafiltration with membranes (10 kD cut off) to approximately 5-8 mL. Solid ammonium sulfate was then added to a final concentration of 1.2 M. This sample was then injected onto a PolyLC, polypropyl aspartamide column, 1000A pore size, 4.6 mm X 200 mm, to resolve proteins by hydrophobic interaction chromatography (HIC). Buffer A was 20 mM Na phosphate, 1.2 M Na sulfate pH 6.3 and Buffer B was 50 M Na phosphate, 5% 2-propanol, pH 7.4. The elution gradient was 0-20% B over 5 minutes; 20-55% B from 5-20 minutes, isocratic at 55% B from 20-23 minutes, 55-100%) B from 23-25 minutes; isocratic at 100% B for 2 minutes before re-equilibration Buffer A. The flow rate was 1 mL/minute. The HIC peak containing hK2 which eluted at about 50% B was exchanged into 50 mM borate buffer pH 8 by repeated concentration with Centricon-10 (Amicon) 10 K MW cutoff ultrafiltration. Purity was assessed by both SDS-PAGE and Western blot analyses. The extinction coefficient used to estimate hK2 v217 concentrations was A 280 of 1.84 = 1 mg/ml. In some cases the HIC peak containing hK2 was purified further by size exclusion chromatography (SEC) on a 10/30 Pharmacia S12 column. In this case the HIC peak containing hK2 was concentrated by ultrafiltration as above to less than 1 mL and then applied to the size exclusion column equilibrated in 100 mM ammonium acetate pH 7 or sodium borate pH 8. The flow rate was 0.7 mL/minute. The hK2 peak was then concentrated by ultrafiltration. The peak collected off SEC in ammonium acetate was lyophilized to remove the buffer and then was reconstituted in water. An aliquot of this sample was hydrolyzed in gaseous 6 N HO under vacuum for 20 hours at 1 12°C then reconstituted in 0.1 N HC1 and analyzed on a Hewlett Packard Aminoquant amino acid analyzer utilizing pre-column derivatization of amino acids with OPA for primary and FMOC for secondary amines. A HKl G 586.1 affinity resin was used to purify hK2 by affinity chromatography. HKlG 586.1 monoclonal antibody (mAb) was coupled with Pharmacia GammaBind plus Sepharose (cat. no. 17-0886) according to Schneider (J. Biol. Chem.. 257. 10766 (1982)). Briefly, HKIG 586.1 mAb and resin were incubated overnight at 4°C with rotation. Resin was centrifuged (500 X g for 5 minutes at 4°C) and washed twice with 0.2 M triethanolamine, pH 8.2. Amine groups were cross-linked in fresh cross linker solution (25 mM dimethyl pimelimidate dihydrochloride in 0.2 M triethanolamine, pH 8.2) for 45 minutes at room temperature (22°C). The resin was quenched with 20 mM ethanolamine, pH 8.2, for 5 minutes at room temperature and then washed twice with 1 M NaCl, 0.1 M PO 4 , pH 7.0. The resin was washed two more times with PBS and stored at 4°C with 0.05% NaN3 until use. An Applied Biosystems Model 477a pulsed liquid phase sequencer was used to sequence the proteins and the peptides. The Model 477a employs automated Edman degradation chemistry to sequentially release amino acids from the N-terminus followed by PTH derivatization and chromatography by reversed-phase HPLC. The peptide samples were applied to the sequencer on biobrene-treated glass fiber filter supports and whole proteins were applied either to biobrene-treated filters or to pre-activated Porton filters (Beckman, Fullerton, CA). Samples sequenced off blots were first run as mini-gels on the Novex system (Novex, San Diego, CA) then transferred to Problot PVDF membrane, visualized with Commassie blue, the appropriate band cut out and sequenced directly from the PVDF membrane. Monoclonal antibody production A/J mice were injected with 50 μl of phK2 in complete Freund's adjuvant (CFA) i.p. on day 1, 25 μg of phK2 in incomplete Freund's adjuvant (IF A) i.p. on day 14 and 25 μg phK2 in PBS i.p. on day 28. Three days prior to fusion, mice were boosted with 10 μg of phK2 in PBS i.v. Mice were sacrificed and a single cell suspension was prepared from the spleens. Immune B cells were fused with P3.653 myeloma cells using techniques well known to the art. Clones were screened by ELISA and selected based on the reactivity of supernatants to hk2 v217 and phK2 v217 and minimal reactivity with PSA. Two clones selected by these criteria, clones HK1G464 and HK1G586, were subcloned using FACStar plus cell sorter to deposit single cells onto mouse spleen feeder layers. Subclones HK1G464.3 and HK1 G586.1 were used for further studies. Another fusion, which employed the same protocol described above except that the immunogen was hK2 v21? , alum was used instead of CFA and IFΛ, BALB/c mice were used instead of A/J mice, produced clone HK1H247. ELISA assays A dried-down ELISA format was used to measure hK2 in the serum-free spent medium of the clones and in the fractions collected during hK2 purification. Microtiter plates (Becton Dickinson Labware, NJ) were coated with 50 μl of spent media or column fractions overnight at 37°C. The wells were washed with PBS + 0.1% Tween 20 (PBST) and incubated for one hour with 50 μl of primary antibodies. The wells were washed again with PBS+T and incubated for one hour at 37°C with 50 μl of goat anti mouse-IgG or goat anti rabbit-IgG Fc antibodies coupled with horseradish peroxidase (1 :500, Jackson Immunosearch Laboratories, Inc., West Grove, PA). The wells were washed with PBST, incubated with o-phenylenediamine dihydrochloride (OPD, Sigma, MO) for 5 minutes, and the colorimetric reaction was measured at A 490 with an ELISA reader (Biotek Instruments, Inc., model EL310, VT). All samples were assayed in duplicate. The serum-free spent medium from AVI 2 cells transfected with vector alone was used as negative control. Antibodies were tested in a solution-based ELISA format using biotinylated phK2 v217 , hK2 v217 , and PSA. PSA was purified by the method of Sensabaugh and Blake . J. Urology. 144. 1523 (1990)). Twenty ng of biotinylated hK2 v217 or phK2 v217 diluted in 50 μl Buffer A (8.82 mM citric acid, 82.1 mM sodium phosphate (dibasic), 10% BSA, 0.1% mannitol, 0.1% Nonidet P-40, pH 7.0) or 0.25 ng biotinylated PSA diluted in 10% horse serum (HS) in PBS was incubated with 50 μl of hybridoma supernatants, negative control supernatants (i.e., irrelevant hybridoma supernatant for phK2 v217 and hK2 v217 , or 20 μg/ml irrelevant purified mAb in HS for PSA), or positive control supernatants (i.e., 20 μg/ml purified PSM773 (anti-PSA) mAb in HS for PSA, or HK1D 104 (anti "hK2") hybridoma supernatant for phK2 v217 and hK2 v2 ' 7 ). HCO514, a mAb against hCG, was used as a negative control in PSA assays, and ZTG085, a mAb against the tau, was used as a negative control in hK2 assays. These mixtures of antibodies and antigens were allowed to incubate for 1 hour with shaking in a streptavidin coated microtiter plate (Labsystems, Helsinki, Finland). The plate was washed 3 times with 300 μl of PBS, 0.1 % Tween-20 (PBST), and incubated with 100 μl of gamma-specific goat anti mouse IgG-horseradish peroxidase conjugate (Jackson ImmunoResearch Laboratories, Inc., Westgrove, PA), diluted 1 : 10,000 in HS, with shaking for 1 hour. After a second PBST washing, color was developed for 30 minutes, with shaking, following the addition of 100 μl of 1 mg/ml o-phenylenediamine in 50 mM phosphate-citrate buffer, 0.03% sodium perborate, pH 5.0 (Sigma Chemical, St. Louis, MO). The reaction was quenched by the addition of 50 μl 4 N H 2 SO 4 . The color intensity was determined by measuring the absorbance at 490 nm and 540 nm using a microtiter plate reader. Absorbances above 2.6 at 490 nm were corrected with 540 nm reading. Sample values are averages ± standard deviation of triplicates. Control values are averages of duplicates. Western blot assays Western blot analyses were performed using standard procedures. Serum-free spent media were concentrated ten fold using Centricon 10 ( Amicon, Inc., Beverly, MA) and subjected to SDS/PAGE using a 12% gel (Bio-Rad, Inc., Melville, NY). For analytical purposes, SDS/PAGE was performed on a Pharmacia PhastSystem using 8-25% gradient gels. After electrophoresis, proteins were transferred onto nitrocellulose membrane and blocked overnight at 4°C with 2% nonfat dried milk in PBS. Blots were rinsed then incubated with primary antibody (1 : 1000 dilution of ascites, or 1 μg/ml of purified mAbs or polyclonal Abs) for I hour at 22 °C. Blots were then washed and incubated for 45 minutes with secondary antibody (Goat anti-mouse-HRP or goat anti-rabbit- HRP, 1 :500, Jackson Immunosearch Laboratories, Inc., West Grove, PA). The immunoreactive bands were detected by developing the blot using DAB (Sigma, St. Louis, MO) plus H 2 O 2 or by using the ECL (Amersham, Buckinghamshire, England) system according to manufacturer's instructions. Covalent complex formation To test for covalent complex formation, 0.175 μM hK2 was incubated with 20 μM of inhibitor at pH 8 in 100 mM borate buffer. Inhibitors tested were 1-antichymotrypsin (ACT), 1 -antitrypsin, 1 -antiplasmin, antithrombin and 2- macroglobulin (MG). To 5 μl of hK2 (10 μg/ml) was added the calculated μg of inhibitor prepared in 100 mM borate buffer and, if needed, each sample brought up to a total volume of 10 μl. Samples were incubated for 3 hours at 37°C whereupon 1.5 μl of 7 X PhastSystem SDS sample buffer containing 35% 2- mercaptoethanol was added and the sample boiled for 3 minutes in a water bath. Samples were diluted 1/4 in SDS sample buffer prior to application to SDS/PAGE and Western analyses. Proteolvsis of Peptide Substrates To determine the ability of hK2 to cleave peptide substrates, peptides were dissolved in DMSO at 10 mg/ml then diluted 1 :10 into 100 mM borate buffer pH 8 containing PSA, hK2 or trypsin. Typical experiments were performed as follows: 1 μl of peptide was added to 7 μl of 100 mM borate buffer and then 2 μl of hK2 (10 μg/ml), PSA (500 μg/ml) or trypsin (0.5 μg/ml) were added. In general, samples were incubated for 16 hours at 37°C. Samples were quenched with 100 μl of 0.2% TF A/water and the quenched sample was applied directly to a Vydac C-18 reversed-phase column attached to a BioRad Model 800 HPLC equipped with an AS 100 autosampler, dual 1350 pumps and Biodimension scanning UV-VIS detector. Solvent A was 0.1 % TF A/water and Solvent B was acetonitrile containing 0.1% TFA. The sample was applied in 90% solvent A and the gradient developed to 60% solvent B in 10 minutes. Absorbance was monitored simultaneously at 220 nm and 280 nm. Peaks collected off HPLC were concentrated by vacuum centrifugation or lyophilization and then applied to the amino acid sequencer to identify individual fragments. In some cases 10 μl of the quenched sample mixture was applied directly to the sequencing membrane and, since the sequence was known, the cleavage sites were determined from the distribution of amino acids present in each cycle. Protease assays using chromogenic substrates Assays to measure the hydrolysis of para-nitroanilide derivatized substrates were performed using an HP 8452A UV-VIS spectrophotometer equipped with a programmable, thermostated 7-position cell holder. Assays were performed in 100 mM sodium borate pH 8 incubated at 37°C, the absorbance increase monitored at 405 nm. Methoxysuccinyl-Arg-Pro-Tyr-para- nitroanilide (MeO-Suc-R-P-Y-pNA) and H-D-pro-phe-arg-para-nitroanilide (P- F-R-pNA) were 1 mM in the assay. An ABI model 431 A peptide synthesizer using standard FastMoc chemistry was employed to synthesize all of the peptides listed in Figure 16 except #2, angiotensinogen and #5, oxidized beta-chain of insulin which were obtained from Sigma. The mass of each synthesized peptide was confirmed by mass spectrometry (University of Michigan, Core Facility) using ES/MS. An ABI Model 477a sequencer described above was employed to confirm peptide sequence. Conversion of nhK2 v217 to hK2 V217 Samples of phK2 v217 at 100-400 μg/ml in 50 mM sodium borate were incubated with 1% w/w trypsin or hK2 at 37°C. The conversion of pro to mature was monitored by dilution of 1-2 μg of hK2 v2,? starting material into 100 μl HIC Buffer A and resolution of the two forms by HIC-HPLC as described above. The incubation of hK2 v217 with phK2 v2,? was conducted in the same manner except that comparable amounts of the two forms were incubated together as seen in Figure 17B. Example 2. Expression and purification of hK2 v217 in mammalian cells To express hK2 in mammalian cell lines, a 0.8 kb fragment encoding the entire coding sequence of hK2 (pphK2) (Figure 2) was amplified using PCR, subcloned into the vector PCR II (TA) and several clones were isolated. The nucleotide sequence of the entire pphK2 insert in a few of these clones was determined to detect any mutations that may have been caused by PCR amplification. Two clones, one having a wild type hK2 insert, TA-hK2, and one having a mutant hK2 insert, TA-hK2 v2 ' 7 , were selected for further analysis. TA- hK2 v2 ' 7 (SEQ ID NO: 14) contains a substitution of T for C at codon 650 of hK2 resulting in a conservative substitution of valine (GTT) for alanine (GCT) at amino acid residue 217 of hK2 (Figure 2). To obtain mammalian expression vectors, pphK2 inserts of TA-hK2 and TA-hK2 v2I? were subcloned into plasmid PGT-d under the control of the GBMT promoter resulting in plasmids pGThK2 and pGThK2 v217 (Figure 3). The GBMT promoter is composed of several regulatory sequences and is activated by the adenovirus El a protein(s) (Berg et al., supra (1992)). To determine whether the product of the pphK2 v217 gene would be expressed in mammalian cells, the plasmid pGThK2 v217 was transfected into AVI 2-664 cells. This cell line is derived from a tumor induced in Syrian hamster by adenovirus type 12 and expresses the adenovirus El a protein. The Ela protein activates the GBMT promoter which results in the expression of the gene product under the control of this promoter. After 2-3 weeks, MTX-resistant clonal cells were isolated and their spent medium were analyzed by Western blots. Several clones were identified which secreted into the media a polypeptide immunoreactive to anti-pphK2 antiserum. One clone (AV12-pGThK2 v217 #2) was selected for further characterization and protein purification. To purify hK2 polypeptides, the serum-free spent medium from AVI 2- pGThK2 v2I? clone #2 was collected after 7 days, concentrated and subjected to anion exchange chromatography (Figure 4A). The peak of hK2 activity eluted at approximately 0.2 M NaCl as determined by ELISA assays (dotted line). The ELISA assay correlated well with the appearance of a ~34 kD band of protein seen by SDS/PAGE in the same fractions. The hK2-positive fractions from the anion exchange column were collected and subjected to hydrophobic interaction chromatography (HIC) (Figure 4B). A major portion of the A 280 was not retained on HIC column. The main peak retained on HIC, which eluted at 22 minutes, also showed the highest peak of activity by ELISA assay (dotted line. Figure 4C). A major protein band at -34 kD was also observed by SDS-P AGE. When the 22 minute peak from HIC was resolved by SEC, typically about 80-90% of the protein A 280 eluted at 19.4 minutes, a retention time consistent with a protein of approximately 34 kD (Figure 4C). The only other protein peak on SEC, eluting at 16.7 minutes, corresponded to a -70 kD protein observed in previous purification steps. To further identify the purified protein, approximately 2.5 μg of the protein was subjected to automated N-terminal analysis which yielded the following sequence: Val-Pro-Leu-Ileu-Gln-Ser-Arg-Ileu-Val-Gly-Gly-Trp-Glu- (SEQ ID NO: 15). No competing sequence was evident from the profile of amino acids released sequentially by the Edman degradation procedure. By analogy to PSA this protein is phK2 v2π , since the known sequence of mature PSA (isolated from seminal fluid) begins with Ileu-Val-Gly- and pPSA and phK2 have been postulated to have an extra 7 amino acids at the N-terminus (Figure 2). Amino acid analysis of this protein yielded an amino acid composition consistent with the predicted sequence of phK2 v217 . This phK2 polypeptide was purified in mg quantities. Example 3. Characterization of phK2 v217 and generation of hK2 v2 To examine the efficiency of the purification scheme employed in Example 2, 1.5 μg of purified phK2 v2 was subjected to SDS/PAGE in the presence or absence of beta-mercaptoethanol (BME), and the gel was stained with silver. Results showed that the phK2 v217 in the sample was about 95% pure (Figure 5). It also showed that phK2 v217 migrated at -30 kD in the absence of BME, and at -34 kD in the presence of BME. This pattern is similar to that observed for the PSA purified from seminal fluid (Figure 5). The amino acid sequence of hK2, deduced from the cDNA sequence, shows the presence of one potential N-Iinked glycosylation site at residue 78 (N- M-S). To determine if this site is glycosylated, phK2 v217 was subjected to SDS/PAGE, transferred to nitrocellulose paper, reacted with digoxigenin (DIG)- coupled lectins followed by horseradish peroxidase labeled anti-DIG. In Figure 6 (lane 1), 2 μg of phK2 was stained with concanavalin A (Con A) suggesting the presence of two nonsubstituted or 2-O-substituted α-mannosyl residues in the protein. Lane 2 shows Con A staining of the positive control glycoprotein, ZCE025 mAB. Both the heavy chains (50 kD) and light chains (25 kD) of this mAb are known to contain N-linked oligosaccharides with mannose cores. Lane 3 shows that a nonglycosylated protein (BSA) fails to react with the Con A lectin. phK2 v2,? also reacted with RCA (Gal bl -4GlcNAc specificity) and AAA, (α(l-6) linked fucose specificity). This pattern of lectin reactivity is consistent with the presence of complex N-linked oligosaccharides. The oligosaccharides on phK2 v217 also contains sialic acid since both SNA (sialic acid linked α(2-6) to galactose) and MAA (sialic acid linked α(2-6) to galactose were reactive with phK2 v217 . The sequence of the pro region of hK2 is VPLIQSR (SEQ ID NO: 12). An enzymatic cleavage at the carboxy-terminal end of the arginine in this pro sequence would convert phK2 to hK2. A mild trypsin digestion was developed to hydrolyze the peptide bond of purified phK2 v217 at this position. phK2 v2l? was incubated with 1% trypsin and the conversion was monitored by HIC-HPLC (Figure 7). This procedure resulted in a complete conversion of phK2 v217 to hK2 v217 . The peak designated hK2 v217 was N-terminally sequenced and shown to begin with the sequence, IVGGWE, which is the N-terminus for the mature form of hK2. No sequence other than the above was detected demonstrating that this mild trypsin treatment does not result in any significant level of non-specific cleavage. SDS/PAGE of trypsin-treated samples showed a small but discernible increase in mobility, generally consistent with a minor reduction in mass of 826 daltons, the mass of the pro peptide. Example 4. Generation of hK2-specific Abs phK2 v217 and hK2 v2l? were used as immunogens to generate monoclonal antibodies (mabs) against hK2. Hybridomas were screened based on high reactivity with hK2 v217 or phK2 v217 and minimal reactivity with PSA. Representatives of mAbs obtained from the hybridomas are shown in Table 1. Immunization with phK2 v217 resulted in mAb HK1G586.1 and HKl G 464.3. HK1G586.1 was hK2-sρecific, since it recognized both phK2 v217 and hK2 v217 but not PSA. On the other hand, HKl G464 was phK2-specific, since it only recognized phK2 v217 and not hK2 v217 or PSA. Table 1 Specificity of various mAbs raised to hK2 v2π and phK2 v217 A. mAbs raised to phK2 v217 B. mAb raised to hK2 V217 Immunization with hK2 v217 resulted in mAb HKl H247. This mAb was hK2-specific since it recognized only hK2 v217 but not phK2 v217 or PSA. These results show that phK2 v217 and hK2 v2 are useful as immunogens in generating mAbs specific for different forms of hK2. Western blot analysis was used to examine if HKl G586 recognizes hK2 in seminal fluid (Figure 8). hK2-immunoreactive bands at -22 kD, -33 kD, and -85 kD were recognized by this mAb. A similar hK2-immunoreactive pattern in seminal fluid was also recently reported by Deperthes et al., Biochem. Biophv. Acta. 1245. 311 (1995). This result indicates that a mAb raised to hK2 v217 recognizes native hK2 in seminal fluid. All the antibodies raised to hK2 v217 or phK2 v217 also recognized the corresponding form of hK2 and phK2 indicating that hK2 and phK2 are immunologically similar to hK2 v217 and phK2 v217 , respectively (see below). Example 5. Expression of hK2 in mammalian cells To express wild type hK2 (hK2) in mammalian cells pGThk2 (Figure 3) was transfected into AVI 2 cells. Several clones expressing an hK2 polypeptide were identified by Western analysis using HK1D 106.4 (a hK2-specific mAb raised to a polypeptide corresponding to amino acid residues 17-71 of hK2). Clone AV12-hK2#27 (AV12-hK2) was selected for further analysis based on its higher hK2 expression level. Cells transfected with vector alone (pGTD) showed no reactivity with HK1D 106.4. ELISA using HK1D 106.4 mAb indicated the presence of -0.5-1 μg/ml of an hK2 polypeptide in the serum-free spent medium of AV12-hK2 at day 7. The same method used in purification of phK2 217 from AV12-hK2 v2 was used to purify hK2 polypeptides from the day 7 spent medium of AV12-hK2. This resulted in low yields of purified hK2 polypeptides which were highly unstable to the purification procedures and thus impractical for use as an immunogen. hK2 polypeptides were partially purified using the above method, subjected to SDS/PAGE, electroblotted and subjected to N-tcrminal amino acid sequencing. This analysis indicated that the hK2 polypeptide in the spent medium of A V 12-hK2 at day 7 has the sequence, I VGGWECEK (SEQ ID NO: 17) at N-terminus. No competing sequence was evident from the profile of amino acids released sequentially by the Edman degradation procedure. By comparison to PSA, this sequence corresponds to mature hK2 (hK2). Amino acid analysis of this protein was also consistent with that of hK2. This finding was intriguing since it showed that predominantly phK2 v2 ' 7 was present in the serum-free spent medium of AV12-hK2 v217 at day 7, whereas predominantly hK2 was present in the serum-free spent medium of AV12-hK2 at day 7. To examine the form of hK2 present in the serum-free medium of AVI 2- hK2 at day 1 this material was partially purified by affinity purification using HKlG 586.1 mAbs. The -34 kD protein was transferred onto PVDF and was subjected to N-terminal analysis revealing a sequence, VPLIQSRIVGG. No competing sequence was evident from the profile of amino acids released sequentially by the Edman degradation procedure. Compared with PSA, this sequence corresponds to phK2. This suggests that the hK2 polypeptide is secreted as the pro form by both AV12-hK2 and AV12-hk2 v2,? cells. However, while phK2 v217 is stable and is not converted to hK2 v2π , phK2 is unstable and is easily converted to hK2 extracellularly. Example 6. Biosynthesis of hK2 To further study the biosynthesis of hK2 in mammalian cells, a time course study was conducted where serum- free spent media from AV12-hK2 clone #27 was collected each day for 8 consecutive days, concentrated and subjected to SDS/PAGE. The proteins were transferred to nitrocellulose membrane and probed with either HK1D 106.4 or HKlG 464.3 mAbs (Figure 9). As also shown in Figure 9, HK1D 106.4 recognizes both phK2 and hK2 whereas HKlG 464.3 recognizes only phK2 as its epitope lies in -7 to +7 region of hK2. Expression of hK2 polypeptides (-34 kD) peaked by day 3 and plateaued thereafter as detected by HKl D 106.4 mAbs. Two other immunoreactive bands migrating at -70 kD and -90 kD were also detected from day 4 onwards. On the other hand, when the same samples were blotted and probed with HKl G 464.3, a gradual reduction in the level of hK2 was detected by day 4. By day 8, very low levels of hK2 were found in the spent medium. This result shows that phK2 is being secreted into the media by AV12-hK2 cells and is gradually converted to hK2 extracellularly. Curiously, -70 kD and -90 kD bands were not observed with HKlG 464.3 mAbs indicating that these bands are either homo-oligomers of hK2 or are hK2 covalently complexed with a yet unknown protein(s). Even though the identity of these bands is not known at this time, they serve as markers for the presence of hK2 in the spent media. In Figure 9, purified phK2 v217 and hK2 v217 proteins were used as controls. To study the biosynthesis of hK2 v217 in AVI 2 cells a similar time course study was conducted on AV12-hK2 v2 clone #2. As shown in Figure 10, expression of hK2 v217 polypeptides peaked by day 3 and did not vary much from day 4 onwards as detected by HK1D 106.4 mAbs. Similar results were obtained when the blot was probed with HKlG 464.3 mAbs (Figure 10). This indicated that AV 12-pGThK2 v217 clone #2 cells are expressing phK2 v2 ' 7 from day 1 onwards and that for at least 8 days thereafter, this protein is not converted to the mature form. These results are in contrast with those of phK2, which is converted to hK2 if left in the media for 8 days, indicating that phK2 v217 is stable in media at 37°C for 8 days. To study whether extracellular conversion of phK2 to hk2 correlates with the viability of AV12-hK2 clone #27 cells in culture, clone #27 cells were counted using trypan blue exclusion. Expression of hK2 in the spent medium was measured by ELISA using both HK1D 106.4 and HKlG 464.3 mAbs. As shown in Figure 1 1, the number of viable cells peaked at 38 million in culture by day 3 and gradually decreased thereafter. By day 8, the number of viable cells were reduced to less than 10 million. The expression of phK2 (measured by HKlG 464.3) also peaked by day 3 and gradually declined thereafter. On the other hand, expression of hK2 (measured by HK1D 106.4) peaked by day 3 but plateaued thereafter. This result indicates that phK2 is secreted by AV12-hK2 cells and a fraction of it is gradually converted extracellularly to hK2 by day 4. Moreover, it shows that conversion of phK2 to hK2 clearly correlates with a decrease in cell viability, indicating that the extracellular proteases released by the dying cells may be one of the factor(s) responsible for this conversion. Expression of hK2 was highest at the point in which cells were most viable. A decrease in hK2 paralleled a decrease in cell viability, suggesting the hK2 is secreted by these cells, as opposed to being released following cell death and lysis. Also, a rise in hK2 corresponded to a drop in phK2, indicating that the pro form of hK2 was automatically converted to the mature form over time. To examine the biosynthesis of hK2 in prostate carcinoma cells hK2 was expressed in DU 145 and PC3 cell lines. pphK2 was cloned into plasmids pLNCX and pLNSX (Miller and Rosman, BioTechniques. 7, 980 (1989)), under the control of the CMV and SV40 promoters, respectively. The resulting plasmids, pLNC-hK2 and pLNS-hK2, respectively, were transfected into PC3 and DU145 cells, respectively, and clones were selected in media containing G418. Clones expressing high levels of hK2 were selected (PC3-hK2 and DU145-hK2) by ELISA and Western blots. To assess the level of hK2 and phK2 in the media, serum-free medium of PC3-hK2 and DU145-hK2 cells were subjected to Western blot analysis using HK1D 106.4 (hK2-specific) and HKlG 464.3 (phK2 -specific) mAbs (Figure 12). Results showed that phK2 is present in the spent medium of both DU145-hK2 and PC3-hK2. This indicates that in prostate carcinoma cells hK2 is secreted as phK2 and is converted to the mature form extracellularly. This finding confirms the results previously obtained with AVI 2 cells. Predominantly phK2 was detected in the spent medium of PC3-hK2 cells even after 7 days, however, predominately hK2 was present in the serum-free medium of DU145-hK2 starting from day 1. This is probably due to abundance of extracellular proteases in DU145 spent medium. To examine whether the above results were limited to just one clone, 3 other independently isolated clones of AV12-hK2 and 4 other independently isolated clones of AV12-hK2 v2π were tested for the expression of hK2 polypeptides. Serum-free spent medium of the clones were collected at day 7 and tested for the expression of hK2 by Western blots using HK1D 106.4 (hK2- specific) and HKlG 464 (phK2-specific) mAbs (Figures 13 and 14). In all of the AV12-hK2 clones, HK1D 106.4 mAb detected not only the major -34 KD band ("hK2") but also the -70 kD and the -90 kD bands that are indicative of the presence of hK2 (Figure 13). HKlG 464.3 detected very low levels of phK2 in all of the AV12-hK2 clones (Figure 14). This result indicates that predominantly hK2 is present in the spent medium of all the AV12-hK2 clones verifying the biosynthetic mechanism established for AV12-hK2 #27 clone. The same analyses were used on AV12-hK2 v2π clones (Figure 14). Results indicated that only phK2 v2 ' 7 was present in the spent medium of these clones at day 7 verifying our findings with the AV12-hk2 v217 clone. The above results collectively suggest that hK2 is expressed as the pro form in mammalian cells and is converted to mature form extracellularly by as yet unknown proteases. These results also suggest that phK2 is present in biological fluids and therefore can be a useful diagnostic marker for pCa and BPH. Example 7. Enzymatic activity and specificity of hK2 and hK2 v217 A small amount of hK2 was purified to sufficient purity to establish its enzymatic activity and substrate specificity. The general activity of hK2 was measured by determining its amidolytic activity chromogenically on p- nitroanilide derivatives of peptides (Table 2). The p-nitroanilide released by proteolytic digestion of these substrates is measured at absorbance A 4ϋ The substrate methoxysuccinyl-Arg-Pro-Tyr-/?αrø-nitroanilide (MeO-Suc-R-P-Y- pNA) is used to measure chymotrypsin-like proteases which cleave at the phenylalanine. This substrate has been used previously to measure the activity of PSA (Christensson et al., Eur. J. Biochem.. 194. 755 (1990)). The substrate H-D-Pro-Phe-Arg-pαra-nitroanalide (P-F-R-pNA) is specific for trypsin-like proteases which cleave at arginine (R). hK2 was found to have overall activity more than 10 times higher than hK2 2 ' 7 on P-F-R-pNA and neither protein showed an ability to hydrolyze MeO- Suc-R-P-Y-pNA, the chymotrypsin substrate. Other comparable substrates containing trypsin-like sites for cleavage (lysine, arginine) were also tested and hK2 was found to hydrolyze the substrate P-F-R-pNA with the highest rate. These findings indicate that hK2 has trypsin-like activity. Table 2 Amidolytic Activity on Chromogenic Substrates Table 2: Amidolytic activity of hK2, hK2 v2 ' 7 , PSA and trypsin on chromogenic substrates. The specificity of hK2 and hK2 v217 was examined in more detail by the use of peptide substrates together with N-terminal amino acid sequence analysis to determine which peptide bonds had been hydrolyzed. Figure 15 shows amidolytic activity on the polypeptide CALPEKPAVYTKVVHYRKWIKDTIAAN (SEQ ID NO: 16), which has both potential trypsin and chymotrypsin cleavage sites. hK2 v217 cleaved at both a trypsin (R-K) and chymotrypsin (Y-R) site with the trypsin-like cleavage at a 2:1 ratio over the chymotrypsin-like cleavage. As a control in these experiments phK2 v217 was also incubated with this peptide and showed no amidolytic activity. hK2 showed specificity different than hK2 v217 towards this peptide substrate. No chymotrypsin-like specificity was seen for hK2 on this substrate and its activity was exclusive for the trypsin-like site (R-K). None of the other lysine (K) residues in this polypeptide were hydrolyzed indicating that the specificity of hK2 was exclusive for the arginine (R) residue. As a control trypsin was also studied on this substrate. Trypsin cleaved all lysine (K) and arginine (R) sites except the K-P bond which is known not to be a site suitable for trypsin cleavage. Trypsin cleaved the R-K site of the 210- 236 substrate (peptide #1 , Figure 16) at rates approximately 4X faster than hK2 and -4000X faster than hK2 v217 . No chymotrypsin-like bonds were cleaved by trypsin. PSA cleaved the Y-R bond primarily. A minor trypsin-like activity on the R-K bond was also seen for PSA (Figure 15). This was consistent with the minor trypsin-like activity previously seen for PSA on the chromogenic substrate (Table 2). Several other peptide substrates were also incubated with hK2 and PSA (Figure 16). In all of the peptides tested, hK2 had specificity only for selected arginines, and PSA primarily for selected tyrosine (Y), phenylalanine (F) and leucine (L) residues. Only peptide #1 in Figure 16 was cleaved by hK2 v217 as detailed by the chromatograms in Figure 15. Example 8. Activation of phK2 v2>7 by hK2 The sequence of peptide #3 in Figure 16 corresponds to amino acid residue -7 to +7 of phK2. This region contains the pro peptide, VPLIQSR, which is found as an N-terminal leader peptide in phK2 v217 . As mentioned above, hK2 was able to cleave this peptide releasing the propeptide region, but hK2 v2π was not. To delineate if hK2 can cleave this pro sequence on a native substrate, its ability to convert phK2 v217 to hK2 v2 ' 7 was monitored. phK2 v217 was incubated with 1% hK2 and the conversion was monitored by the HIC-HPLC method (Figure 17A). Results showed that hK2 was able to convert phK2 v2 ' 7 to hK2 v2 , albeit at a rate -30X slower than trypsin. When phK2 v2 ' 7 was incubated with 40%) hK2 v217 , no difference in the ratios of the two hK2 forms was detected even after 6 hours (Figure 17B). This corroborated previous observations with the peptide substrate and showed that, even on a native substrate only hK2, and not hK2 v2 , cleaved the pro region of hK2. These results collectively demonstrate the stability of phK2 v 17 and hK2 v217 upon extended incubation. When compared with hK2 v217 , hK2 was shown to have a higher proteolytic activity, higher degree of specificity and, in particular, to have a specificity for the pro form of hK2 as demonstrated by activity on the pro peptide in Figure 15 and by its activity toward phK2 v217 , as shown in Figure 17. These results demonstrate a significant difference in enzymatic activity between hK2 and hK2 v217 and may help explain the low yields obtained following attempts to purify hK2 from the medium, compared to yields of phK2 v217 . Highly purified preparations of hK2 may not be stable due to autolysis, as seen for other active proteases. These results further suggest that, in addition to immunological tests, tests to determine its enzymatic activity on hK2-specific substrates could be used to monitor the level of hK2 in bodily fluids. Example 9. Formation of inhibitor complexes with hK2 PSA has been shown to form complexes with α2 macroglobulin (MG) and the serine protease inhibitor, antichymotrypsin (ACT). To explore its complex formation, hK2 was incubated with a series of common proteases present in human plasma (ACT, α2-antiplasmin, antithrombin III, and αl - antitrypsin (Travis and Salvesen, Ann. Rev. Biochem.. 52, 655 (1983)) and the mixtures were analyzed by Western blot (Figure 18). Any covalent complex of hK2 with these serpins should result in -80-100 kD band on SDS/PAGE under reducing conditions. ACT and 0.2-antiplasmin significantly formed complexes with hK2 (Figure 18, lane 1 and 2). Antithrombin III (lane 3) and α 1 -antitrypsin (αl protease inhibitor, lane 4) formed no detectable complex with hK2. MG, a major component of blood plasma, also rapidly complexed with hK2 (lane 5). This complex corresponds to Mr of -200 kD and 120 kD, which were also formed when PSA was incubated with purified MG (Figure 18, lane 8, see below). It was particularly interesting that hK2 did not form complexes with αl - antitrypsin, even though this protein inhibits a wide range of trypsin-like proteases (Loebermann et al., J. Mol. Biol.. 177. 531 (1984); Carrell and Travis, TIBS, 10, 20 (1985)). It was not surprising that hK2 formed a complex with α2-antiplasmin since this protein has arginine residues in its inhibitor active site (Hunt and Dayhoff, Biochem. Biophv. Res. Comm.. 95, 864 (1980); Chandra et al., Biochemistry. 22, 5055 (1983); Potempa, et al., Science. 241. 699 (1985); Shieh et al.. J. Biol. Chem.. 264. 13420 (19891: Mast et al.. Biochemistry. 30. 1723 ( 1991 )). It was not expected that hK2 would form a complex with ACT, since ACT has a leucine in its inhibitor active site. Clearly, the structural similarities between PSA and hK2 influence their complex formation with a common inhibitor even though their proteolytic specificity is entirely different as demonstrated in Figure 16 and Table 2. When spiked into human female serum, hK2 rapidly formed a complex with MG as detected by Western blot (Figure 18). Lane 1 and lane 3 are hK2- and serum-only controls, respectively. Lane 2 is hK2 incubated with ACT showing the 90 kD hK2-ACT complex and residual hK2. Lanes 4 and 5 are hK2 spiked into serum for 15 minutes and 1 hour, respectively. Lane 6 is hK2 incubated with purified MG for 4 hours. Lane 7 is PSA spiked into serum for 15 minutes and Lane 8 is PSA incubated with purified MG for 4 hours. These results show that MG forms the major complex when hK2 or PSA are spiked into human serum in in vitro experiments. Since a PSA complex with ACT is known to occur in the blood serum of patients with prostate disease, it is likely that hK2 present in serum also forms some level of a complex with ACT. Discussion The in vivo protein processing and secretion mechanisms for PSA or hK2 are not known. The results presented herein show that phK2 is secreted by AV12-hK2, DU145-hK2, and PC3-hK2 cells, indicating that hK2 is normally secreted as phK2 and the propeptide is cleaved extracellularly. This suggests that phK2 exists in biological fluids and thus could be a useful diagnostic marker for pCa or BPH. Both the mutant form of hK2 (hK2 v217 ) and the wild type form of hK2 were purified from AVI 2 cells. hK2 was very unstable to the purification procedures employed which, as found with other proteases, may be due to its autocatalytic property, and makes it very difficult to purify hK2 or phK2 in quantities sufficient for use as immunogens and calibrators. In contrast, phK2 v217 is highly stable and is converted to hK2 v2 ' 7 , which was also stable, by trypsin digestion. Purified phK2 v217 and hK2 v217 provided immunogens to generate mAbs specific for hK2 and phK2. Example 10. Detection of hK2 Polypeptides in Prostate Cancer Cell Line Supernatant Although PSA is a widely used diagnostic marker for prostate cancer (PCa), the detection of PSA cannot distinguish between PCa and benign prostatic hyperplasia. To determine whether phK2 could be detected in the supernatant of a prostate carcinoma cell line, supernatants from LNCaP cells, which naturally secrete both hK2 and PSA, were incubated with hK2-specific antisera. A sequential sandwich assay using streptavidin microtiter plates was employed to measure phK2. Pro hK2-specific mab HK1G464 was biotinylated and used as the capture reagent. MAb HK1H449, which detects both phK2 and hK2, was europium labeled and used as the detector reagent. Time resolved immunofluorescence was measured using a Delfia fluorometer. Assay calibration was achieved by diluting purified phK2 v217 to varying levels from 0 to 100 ng/mL (Figure 20). The assay was tested for cross reactivity to PSA using purified PSA from seminal fluid. PSA at 10 μg/mL yielded a cross reactivity of 0.1 %. In addition, an assay that detects both phK2 and hK2 was established in an analogous manner using biotinylated mab HK1G586 as the capture reagent. PSA cross reactivity for this assay was 0.3%. LNCaP cells were cultured to 80% confluence in RPMI + 10% fetal calf serum. The growth media was aspirated, and the plates were washed with 1 X PBS. HH4 + 10 nM mibolerone was added, and the spent media was collected for 4 days. Viable cells were enumerated by trypan blue staining. The samples were concentrated 4 fold and assayed for PSA (Tandem®-R, Hybritech, Inc., San Diego, CA), phK2 (HK1G464 capture) and phK2 + hK2 (HK1G586 capture). In addition, hK2 enzymatic activity was measured using a hK2- specific chromogenic substrate (Figure 21 ). The assay results showed that both phK2 and hK2 were expressed by prostatic carcinoma cells. phK2 and hK2 levels reached a maximum by day 2 while PSA levels continued to increase. hK2 enzymatic activity increased throughout the time course which suggests that phK2 is converted to hK2 over time. Aliquots of LNCaP samples, which were normalized to HK1G586 hK2 immunoreactivity, as well as hK2, phK2, PSA, pphK2, and ppPSA samples as controls, were applied to a 4-20%) Novex Tris/Gly SDS PAGE and then electroblotted to nitrocellulose. The blots were probed using either HK1G464 (20 μg/mL) or HKl G586 (2 μg/mL) as a primary antibody. After a 2 hour incubation with primary antibody at room temperature, the blots were washed and then probed with a goat anti-mouse HRP secondary antibody. After a one hour incubation with the secondary antibody at room temperature, the blots were washed prior to development with ECL. The results showed that neither HK1G464 nor HK1G586 recognized PSA or ppPSA (Figures 22 and 23, lanes 3 and 5, respectively). Moreover, HK1G464 is phK2 specific since it recognized only phK2 (Figure 22, lane 2) and not hK2 (Figure 22, lane 1) whereas HK1G586 recognized both phK2 and hK2 (Figure 23, lanes 1 and 2, respectively). In addition, Figure 22 (lanes 6-9) showed that HK1G464 detects phK2 (33 kD band) in all LNCaP samples indicating that phK2 is secreted from LNCaP cells. There was approximately 15 ng of HK1G586 immunoreactivity in each lane of lanes 6-9 in Figures 22 and 23. These results indicate that in prostate carcinoma cells hK2 is secreted as phK2. The results also suggest that phK2 may exist in biological fluids and thus could be a useful diagnostic marker for PCa or BPH. Example 11. Detection of hK2 complexes in Prostate Cancer Patient Sera To determine whether hK2 polypeptides exist in biological fluids, ten serum samples from prostate carcinoma patients were evaluated by Western blot with the anti-hK2 mab, HKl G586.1. The PSA levels in each of the serum specimens was determined by immunoradiometric assay (Tandem-R PSA, Hybritech, San Diego, California). Each sera was enriched for hK2 by absorption and elution from an anti-hK2 (HK1G586.1) immunoaffinity column. Enriched sera was prepared by incubating 200 μl of serum with 75 μl of AminoLink Gel (Pierce, Rockford, IL) which had previously been coupled with the anti-hK2 mab, HK1G586.1 according to manufacturer's instructions. Incubation was carried out for 4.5 hours at room temperature on a shaker. The beads were washed four times in 5 mis of phosphate buffered saline containing 0.1% Tween 20. The hK2 was eluted from the beads by incubation with a minimal volume of 2.0% SDS in 0.5 M Tris-HCl, pH 8.0. Reduced and denatured proteins were electrophoresed on 4-20%> polyacrylamide gels and blotted onto nitrocellulose. Successful transfer was checked by staining blots with Ponceau S protein stain. Blots were blocked in 5% nonfat dry milk in PBS and then incubated with antibodies (10 μg/ml) at 4°C overnight. Following washes, secondary antibodies conjugated to horseradish peroxidase (1 :2000 dilution) were incubated with the blots for 1 hour, followed by washes with PBS. Antibody reactivity was detected by the addition of 10 mg/ml diaminobenzidine, 0.1%) hydrogen peroxide in PBS or using the ECL system (Amersham, Arlington Heights, Illinois). In experiments where ECL detection was used, blots were incubated with antibodies for 1 hour at room temperature and exposed to X-ray film, typically for 30 seconds. The majority of the enriched serum samples (7/10) contained a 33 kD species as well as a 90 kD species following detection with the anti-hK2 mab, HK1G586.1 (Figure 24, Lane 1). The three seras which did not react with HK1G586.1 contained low levels of PSA (Table 3). Pools of normal female sera and normal male sera were also negative on Western blots with HKl G586.1. This data suggests that the levels of hK2 in sera appear to correlate with levels of PSA. Free and complexed hK2 were detected by Western blot analysis of prostate carcinoma serum with anti-hK2 mab, HKl G586.1. Prostate carcinoma patient sera was enriched for hK2 by absoφtion and elution from an anti-hK2 (HK1G586.1) immunoaffinity column. The eluted material was examined on Western blot with anti-hK2 mab, HKl G586.1 (Figure 25). In lane 1 , HK1 G586.1 reacted with free hK2 at approximately 33 kD. A higher molecular species at approximately 90 kD was also detected with HKl G586.1. This 90 kD species was also detected with the anti-ACT mab, AC 1A086 (lane 3). The detection of the same band in the immunopurified hK2 by the specific anti-hK2 mab as well as the anti-ACT mab identified this 90 kD species as hK2-ACT. Probing of a similar blot with an anti-PCI (protein C inhibitor) polyclonal antibody did not produce any signal, indicating that an hK2-PCI complex could not be detected in an enriched preparation of prostate cancer serum. The band at 50 kD consistently seen across the blot represents the detection of immunoglobulin which is released from the immunoaffinity resin during the elution process and then detected by the secondary antibody, goat anti-mouse- HRP in the Western blot procedure. The large band at approximately 66 kD, which is only detected with the anti-ACT mab, represents free ACT. Thus, hK2 polypeptides are present in biological fluids of prostate cancer patients. Therefore, the detection of these polypeptides could be a useful diagnostic marker for PCa or BPH. Table 3 Detection of hK2 in Prostate Cancer Patient Serum by Western Blot Analysis with HK1G586.1 All publications and patents are incoφorated by reference herein, as though individually incoφorated by reference. The invention is not limited to the exact details shown and described, for it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention defined by the claims. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Mayo Foundation for Medical Education and Research, and Hybritech, Incorporated (ii) TITLE OF INVENTION: Methods to Detect hK2 Polypeptides (iii) NUMBER OF SEQUENCES: 22 (iv) CORRESPONDENCE ADDRESS : (A) ADDRESSEE: Schwegman, Lundberg & Woessner, P.A. (B) STREET: P. O. Box 2938 (C) CITY: Minneapolis (D) STATE: MN (E) COUNTRY: USA (F) ZIP: 55402 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 <vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: Unknown (B) FILING DATE: Herewith (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/580,868 (B) FILING DATE: 15-JULY-1996 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Woessner, Warren D. (B) REGISTRATION NUMBER: 30,440 (C) REFERENCE/DOCKET NUMBER: 545.003US1 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 612-339-0331 (B) TELEFAX: 612-339-3061 (2) INFORMATION FOR SEQ ID NO : 1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 237 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: lie Val Gly Gly Trp Glu Cys Glu Lys His Ser Gin Pro Trp Gin Val 1 5 10 15 Ala Val Tyr Ser His Gly Trp Ala His Cys Gly Gly Val Leu Val His 20 25 30 Pro Gin Trp Val Leu Thr Ala Ala His Cys Leu Lys Lys Asn Ser Gin 35 40 45 Val Trp Leu Gly Arg His Asn Leu Phe Glu Pro Glu Asp Thr Gly Gin 50 55 60 Arg Val Pro Val Ser His Ser Phe Pro His Pro Leu Tyr Asn Met Ser 65 70 75 80 Leu Leu Lys His Gin Ser Leu Arg Pro Asp Glu Asp Ser Ser His Asp 85 90 95 Leu Met Leu Leu Arg Leu Ser Glu Pro Ala Lys lie Thr Asp Val Val 100 105 110 Lys Val Leu Gly Leu Pro Thr Gin Glu Pro Ala Leu Gly Thr Thr Cys 115 120 125 Tyr Ala Ser Gly Trp Gly Ser lie Glu Pro Glu Glu Phe Leu Arg Pro 130 135 140 Arg Ser Leu Gin Cys Val Ser Leu His Leu Leu Ser Asn Asp Met Cys 145 150 155 160 Ala Arg Ala Tyr Ser Glu Lys Val Thr Glu Phe Met Leu Cys Ala Gly 165 170 175 Leu Trp Thr Gly Gly Lys Asp Thr Cys Gly Gly Asp Ser Gly Gly Pro 180 185 190 Leu Val Cys Asn Gly Val Leu Gin Gly lie Thr Ser Trp Gly Pro Glu 195 200 205 Pro Cys Ala Leu Pro Glu Lys Pro Ala Val Tyr Thr Lys Val Val His 210 215 220 Tyr Arg Lys Trp lie Lys Asp Thr lie Ala Ala Asn Pro 225 230 235 (2) INFORMATION FOR SEQ ID NO : 2 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 711 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (x ) SEQUENCE DESCRIPTION: SEQ ID NO:2: ATT GTG GGA GGC TGG GAG TGT GAG AAG CAT TCC CAA CCC TGG CAG GTG 48 lie Val Gly Gly Trp Glu Cys Glu Lys His Ser Gin Pro Trp Gin Val 1 5 10 15 GCT GTG TAC AGT CAT GGA TGG GCA CAC TGT GGG GGT GTC CTG GTG CAC 96 Ala Val Tyr Ser His Gly Trp Ala His Cys Gly Gly Val Leu Val His 20 25 30 CCC CAG TGG GTG CTC ACA GCT GCC CAT TGC CTA AAG AAG AAT AGC CAG 144 Pro Gin Trp Val Leu Thr Ala Ala His Cys Leu Lys Lys Asn Ser Gin 35 40 45 GTC TGG CTG GGT CGG CAC AAC CTG TTT GAG CCT GAA GAC ACA GGC CAG 192 Val Trp Leu Gly Arg His Asn Leu Phe Glu Pro Glu Asp Thr Gly Gin 50 55 60 AGG GTC CCT GTC AGC CAC AGC TTC CCA CAC CCG CTC TAC AAT ATG AGC 240 Arg Val Pro Val Ser His Ser Phe Pro His Pro Leu Tyr Asn Met Ser 65 70 75 80 CTT CTG AAG CAT CAA AGC CTT AGA CCA GAT GAA GAC TCC AGC CAT GAC 288 Leu Leu Lys His Gin Ser Leu Arg Pro Asp Glu Asp Ser Ser His Asp 85 90 95 CTC ATG CTG CTC CGC CTG TCA GAG CCT GCC AAG ATC ACA GAT GTT GTG 336 Leu Met Leu Leu Arg Leu Ser Glu Pro Ala Lys lie Thr Asp Val Val 100 105 110 AAG GTC CTG GGC CTG CCC ACC CAG GAG CCA GCA CTG GGG ACC ACC TGC 384 Lys Val Leu Gly Leu Pro Thr Gin Glu Pro Ala Leu Gly Thr Thr Cys 115 120 125 TAC GCC TCA GGC TGG GGC AGC ATC GAA CCA GAG GAG TTC TTG CGC CCC 432 Tyr Ala Ser Gly Trp Gly Ser lie Glu Pro Glu Glu Phe Leu Arg Pro 130 135 140 AGG AGT CTT CAG TGT GTG AGC CTC CAT CTC CTG TCC AAT GAC ATG TGT 480 Arg Ser Leu Gin Cys Val Ser Leu His Leu Leu Ser Asn Asp Met Cys 145 150 155 160 GCT AGA GCT TAC TCT GAG AAG GTG ACA GAG TTC ATG TTG TGT GCT GGG 528 Ala Arg Ala Tyr Ser Glu Lys Val Thr Glu Phe Met Leu Cys Ala Gly 165 170 175 CTC TGG ACA GGT GGT AAA GAC ACT TGT GGG GGT GAT TCT GGG GGT CCA 576 Leu Trp Thr Gly Gly Lys Asp Thr Cys Gly Gly Asp Ser Gly Gly Pro 180 185 190 CTT GTC TGT AAT GGT GTG CTT CAA GGT ATC ACA TCA TGG GGC CCT GAG 624 Leu Val Cys Asn Gly Val Leu Gin Gly lie Thr Ser Trp Gly Pro Glu 195 200 205 CCA TGT GCC CTG CCT GAA AAG CCT GCT GTG TAC ACC AAG GTG GTG CAT 672 Pro Cys Ala Leu Pro Glu Lys Pro Ala Val Tyr Thr Lys Val Val His 210 215 220 TAC CGG AAG TGG ATC AAG GAC ACC ATC GCA GCC AAC CCC 711 Tyr Arg Lys Trp He Lys Asp Thr He Ala Ala Asn Pro 225 230 235 (2) INFORMATION FOR SEQ ID NO : 3 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 244 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 3 : Val Pro Leu He Gin Ser Arg He Val Gly Gly Trp Glu Cys Glu Lys 1 5 10 15 His Ser Gin Pro Trp Gin Val Ala Val Tyr Ser His Gly Trp Ala His 20 25 30 Cys Gly Gly Val Leu Val His Pro Gin Trp Val Leu Thr Ala Ala His 35 40 45 Cys Leu Lys Lys Asn Ser Gin Val Trp Leu Gly Arg His Asn Leu Phe 50 55 60 Glu Pro Glu Asp Thr Gly Gin Arg Val Pro Val Ser His Ser Phe Pro 65 70 75 80 His Pro Leu Tyr Asn Met Ser Leu Leu Lys His Gin Ser Leu Arg Pro 85 90 95 Asp Glu Asp Ser Ser His Asp Leu Met Leu Leu Arg Leu Ser Glu Pro 100 105 110 Ala Lys He Thr Asp Val Val Lys Val Leu Gly Leu Pro Thr Gin Glu 115 120 125 Pro Ala Leu Gly Thr Thr Cys Tyr Ala Ser Gly Trp Gly Ser He Glu 130 135 140 Pro Glu Glu Phe Leu Arg Pro Arg Ser Leu Gin Cys Val Ser Leu His 145 150 155 160 Leu Leu Ser Asn Asp Met Cys Ala Arg Ala Tyr Ser Glu Lys Val Thr 165 170 175 Glu Phe Met Leu Cys Ala Gly Leu Trp Thr Gly Gly Lys Asp Thr Cys 180 185 190 Gly Gly Asp Ser Gly Gly Pro Leu Val Cys Asn Gly Val Leu Gin Gly 195 200 205 He Thr Ser Trp Gly Pro Glu Pro Cys Ala Leu Pro Glu Lys Pro Ala 210 215 220 Val Tyr Thr Lys Val Val His Tyr Arg Lys Trp He Lys Asp Thr He 225 230 235 240 Ala Ala Asn Pro (2) INFORMATION FOR SEQ ID NO : 4 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 766 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..732 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: GTG CCC CTC ATC CAG TCT CGG ATT GTG GGA GGC TGG GAG TGT GAG AAG 48 Val Pro Leu He Gin Ser Arg He Val Gly Gly Trp Glu Cys Glu Lys 1 5 10 15 CAT TCC CAA CCC TGG CAG GTG GCT GTG TAC AGT CAT GGA TGG GCA CAC 96 His Ser Gin Pro Trp Gin Val Ala Val Tyr Ser His Gly Trp Ala His 20 25 30 TGT GGG GGT GTC CTG GTG CAC CCC CAG TGG GTG CTC ACA GCT GCC CAT 144 Cys Gly Gly Val Leu Val His Pro Gin Trp Val Leu Thr Ala Ala His 35 40 45 TGC CTA AAG AAG AAT AGC CAG GTC TGG CTG GGT CGG CAC AAC CTG TTT 192 Cys Leu Lys Lys Asn Ser Gin Val Trp Leu Gly Arg His Asn Leu Phe 50 55 60 GAG CCT GAA GAC ACA GGC CAG AGG GTC CCT GTC AGC CAC AGC TTC CCA 240 Glu Pro Glu Asp Thr Gly Gin Arg Val Pro Val Ser His Ser Phe Pro 65 70 75 80 CAC CCG CTC TAC AAT ATG AGC CTT CTG AAG CAT CAA AGC CTT AGA CCA 288 His Pro Leu Tyr Asn Met Ser Leu Leu Lys His Gin Ser Leu Arg Pro 85 90 95 GAT GAA GAC TCC AGC CAT GAC CTC ATG CTG CTC CGC CTG TCA GAG CCT 336 Asp Glu Asp Ser Ser His Asp Leu Met Leu Leu Arg Leu Ser Glu Pro 100 105 110 GCC AAG ATC ACA GAT GTT GTG AAG GTC CTG GGC CTG CCC ACC CAG GAG 384 Ala Lys He Thr Asp Val Val Lys Val Leu Gly Leu Pro Thr Gin Glu 115 120 125 CCA GCA CTG GGG ACC ACC TGC TAC GCC TCA GGC TGG GGC AGC ATC GAA 432 Pro Ala Leu Gly Thr Thr Cys Tyr Ala Ser Gly Trp Gly Ser He Glu 130 135 140 CCA GAG GAG TTC TTG CGC CCC AGG AGT CTT CAG TGT GTG AGC CTC CAT 480 Pro Glu Glu Phe Leu Arg Pro Arg Ser Leu Gin Cys Val Ser Leu His 145 150 155 160 CTC CTG TCC AAT GAC ATG TGT GCT AGA GCT TAC TCT GAG AAG GTG ACA 528 Leu Leu Ser Asn Asp Met Cys Ala Arg Ala Tyr Ser Glu Lys Val Thr 165 170 175 GAG TTC ATG TTG TGT GCT GGG CTC TGG ACA GGT GGT AAA GAC ACT TGT 576 Glu Phe Met Leu Cys Ala Gly Leu Trp Thr Gly Gly Lys Asp Thr Cys 180 185 190 GGG GGT GAT TCT GGG GGT CCA CTT GTC TGT AAT GGT GTG CTT CAA GGT 624 Gly Gly Asp Ser Gly Gly Pro Leu Val Cys Asn Gly Val Leu Gin Gly 195 200 205 ATC ACA TCA TGG GGC CCT GAG CCA TGT GCC CTG CCT GAA AAG CCT GCT 672 He Thr Ser Trp Gly Pro Glu Pro Cys Ala Leu Pro Glu Lys Pro Ala 210 215 220 GTG TAC ACC AAG GTG GTG CAT TAC CGG AAG TGG ATC AAG GAC ACC ATC 720 Val Tyr Thr Lys Val Val His Tyr Arg Lys Trp He Lys Asp Thr He 225 230 235 240 GCA GCC AAC CCC TGAGTGCCCC TGTCCCACCC CTACCTCTAG TAAA 766 Ala Ala Asn Pro (2) INFORMATION FOR SEQ ID NO : 5 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 261 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: Met Trp Asp Leu Val Leu Ser He Ala Leu Ser Val Gly Cys Thr Gly 1 5 10 15 Ala Val Pro Leu He Gin Ser Arg He Val Gly Gly Trp Glu Cys Glu 20 25 30 Lys His Ser Gin Pro Trp Gin Val Ala Val Tyr Ser His Gly Trp Ala 35 40 45 His Cys Gly Gly Val Leu Val His Pro Gin Trp Val Leu Thr Ala Ala 50 55 60 His Cys Leu Lys Lys Asn Ser Gin Val Trp Leu Gly Arg His Asn Leu 65 70 75 80 Phe Glu Pro Glu Asp Thr Gly Gin Arg Val Pro Val Ser His Ser Phe 85 90 95 Pro His Pro Leu Tyr Asn Met Ser Leu Leu Lys His Gin Ser Leu Arg 100 105 110 Pro Asp Glu Asp Ser Ser His Asp Leu Met Leu Leu Arg Leu Ser Glu 115 120 125 Pro Ala Lys He Thr Asp Val Val Lys Val Leu Gly Leu Pro Thr Gin 130 135 140 Glu Pro Ala Leu Gly Thr Thr Cys Tyr Ala Ser Gly Trp Gly Ser He 145 150 155 160 Glu Pro Glu Glu Phe Leu Arg Pro Arg Ser Leu Gin Cys Val Ser Leu 165 170 175 His Leu Leu Ser Asn Asp Met Cys Ala Arg Ala Tyr Ser Glu Lys Val 180 185 190 Thr Glu Phe Met Leu Cys Ala Gly Leu Trp Thr Gly Gly Lys Asp Thr 195 200 205 Cys Gly Gly Asp Ser Gly Gly Pro Leu Val Cys Asn Gly Val Leu Gin 210 215 220 Gly He Thr Ser Trp Gly Pro Glu Pro Cys Ala Leu Pro Glu Lys Pro 225 230 235 240 Ala Val Tyr Thr Lys Val Val His Tyr Arg Lys Trp He Lys Asp Thr 245 250 255 He Ala Ala Asn Pro 260 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 832 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 10..792 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: GGATCCAGC ATG TGG GAC CTG GTT CTC TCC ATC GCC TTG TCT GTG GGG 48 Met Trp Asp Leu Val Leu Ser He Ala Leu Ser Val Gly 1 5 10 TGC ACT GGT GCC GTG CCC CTC ATC CAG TCT CGG ATT GTG GGA GGC TGG 96 Cys Thr Gly Ala Val Pro Leu He Gin Ser Arg He Val Gly Gly Trp 15 20 25 GAG TGT GAG AAG CAT TCC CAA CCC TGG CAG GTG GCT GTG TAC AGT CAT 144 Glu Cys Glu Lys His Ser Gin Pro Trp Gin Val Ala Val Tyr Ser His 30 35 40 45 GGA TGG GCA CAC TGT GGG GGT GTC CTG GTG CAC CCC CAG TGG GTG CTC 192 Gly Trp Ala His Cys Gly Gly Val Leu Val His Pro Gin Trp Val Leu 50 55 60 ACA GCT GCC CAT TGC CTA AAG AAG AAT AGC CAG GTC TGG CTG GGT CGG 240 Thr Ala Ala His Cys Leu Lys Lys Asn Ser Gin Val Trp Leu Gly Arg 65 70 75 CAC AAC CTG TTT GAG CCT GAA GAC ACA GGC CAG AGG GTC CCT GTC AGC 288 His Asn Leu Phe Glu Pro Glu Asp Thr Gly Gin Arg Val Pro Val Ser 80 85 90 CAC AGC TTC CCA CAC CCG CTC TAC AAT ATG AGC CTT CTG AAG CAT CAA 336 His Ser Phe Pro His Pro Leu Tyr Asn Met Ser Leu Leu Lys His Gin 95 100 105 AGC CTT AGA CCA GAT GAA GAC TCC AGC CAT GAC CTC ATG CTG CTC CGC 384 Ser Leu Arg Pro Asp Glu Asp Ser Ser His Asp Leu Met Leu Leu Arg 110 115 120 125 CTG TCA GAG CCT GCC AAG ATC ACA GAT GTT GTG AAG GTC CTG GGC CTG 432 Leu Ser Glu Pro Ala Lys He Thr Asp Val Val Lys Val Leu Gly Leu 130 135 140 CCC ACC CAG GAG CCA GCA CTG GGG ACC ACC TGC TAC GCC TCA GGC TGG 480 Pro Thr Gin Glu Pro Ala Leu Gly Thr Thr Cys Tyr Ala Ser Gly Trp 145 150 155 GGC AGC ATC GAA CCA GAG GAG TTC TTG CGC CCC AGG AGT CTT CAG TGT 528 Gly Ser He Glu Pro Glu Glu Phe Leu Arg Pro Arg Ser Leu Gin Cys 160 165 170 GTG AGC CTC CAT CTC CTG TCC AAT GAC ATG TGT GCT AGA GCT TAC TCT 576 Val Ser Leu His Leu Leu Ser Asn Asp Met Cys Ala Arg Ala Tyr Ser 175 180 185 GAG AAG GTG ACA GAG TTC ATG TTG TGT GCT GGG CTC TGG ACA GGT GGT 624 Glu Lys Val Thr Glu Phe Met Leu Cys Ala Gly Leu Trp Thr Gly Gly 190 195 200 205 AAA GAC ACT TGT GGG GGT GAT TCT GGG GGT CCA CTT GTC TGT AAT GGT 672 Lys Asp Thr Cys Gly Gly Asp Ser Gly Gly Pro Leu Val Cys Asn Gly 210 215 220 GTG CTT CAA GGT ATC ACA TCA TGG GGC CCT GAG CCA TGT GCC CTG CCT 720 Val Leu Gin Gly He Thr Ser Trp Gly Pro Glu Pro Cys Ala Leu Pro 225 230 235 GAA AAG CCT GCT GTG TAC ACC AAG GTG GTG CAT TAC CGG AAG TGG ATC 768 Glu Lys Pro Ala Val Tyr Thr Lys Val Val His Tyr Arg Lys Trp He 240 245 250 AAG GAC ACC ATC GCA GCC AAC CCC TGAGTGCCCC TGTCCCACCC CTACCTCTAG 822 Lys Asp Thr He Ala Ala Asn Pro 255 260 TAAACTGCAG 832 (2) INFORMATION FOR SEQ ID NO : 7 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 237 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 7 : He Val Gly Gly Trp Glu Cys Glu Lys His Ser Gin Pro Trp Gin Val 1 5 10 15 Leu Val Ala Ser Arg Gly Arg Ala Val Cys Gly Gly Val Leu Val His 20 25 30 Pro Gin Trp Val Leu Thr Ala Ala His Cys He Arg Asn Lys Ser Val 35 40 45 He Leu Leu Gly Arg His Ser Leu Phe His Pro Glu Asp Thr Gly Gin 50 55 60 Val Phe Gin Val Ser Thr Ser Phe Pro His Pro Leu Tyr Asp Met Ser 65 70 75 80 Leu Leu Lys Asn Arg Phe Leu Arg Pro Gly Asp Asp Ser Ser His Asp 85 90 95 Leu Met Leu Leu Arg Leu Ser Glu Pro Ala Glu Leu Thr Asp Ala Val 100 105 110 Lys Val Met Asp Leu Pro Thr Gin Glu Pro Ala Leu Gly Thr Thr Cys 115 120 125 Tyr Ala Ser Gly Trp Gly Ser He Glu Pro Glu Glu Phe Leu Thr Pro 130 135 140 Lys Lys Leu Gin Cys Val Gin Leu His Val He Ser Asn Asp Val Cys 145 150 155 160 Ala Gin Val His Pro Gin Lys Val Thr Lys Phe Met Leu Cys Ala Gly 165 170 175 Arg Trp Thr Gly Gly Lys Ser Thr Cys Ser Gly Asp Ser Gly Gly Pro 180 185 190 Leu Val Cys Asn Gly Val Leu Gin Gly He Thr Ser Trp Gly Ser Glu 195 200 205 Pro Cys Ala Leu Pro Glu Arg Pro Ser Leu Tyr Thr Lys Val Val His 210 215 220 Tyr Arg Lys Trp He Lys Asp Thr He Val Ala Asn Pro 225 230 235 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 8 : ACGCGGATCC AGCATGTGGG ACCTGGTTCT CT 32 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 9 : ACAGCTGCAG TTTACTAGAG GTAGGGGTGG GAC 33 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE- nucleic acid (C) STRANDEDNESS- single (D) TOPOLOGY, linear (11) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: ATATGGATCC ATATGTCAGC ATGTGGGACC TGGTTCTCTC CA 42 (2) INFORMATION FOR SEQ ID NO: 11 (l) SEQUENCE CHARACTERISTICS- (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS single (D) TOPOLOGY: linear (n) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: ATATGGATCC TCAGGGGTTG GCTGCGATGG T 31 (2) INFORMATION FOR SEQ ID NO: 12: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 ammo acids (B) TYPE: ammo acid (C) STRANDEDNESS: single (D) TOPOLOGY, linear (n) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Val Pro Leu He Gin Ser Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 13: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 832 base pairs (B) TYPE: nucleic ac d (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ll) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 10..792 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: GGATCCAGC ATG TGG GAC CTG GTT CTC TCC ATC GCC TTG TCT GTG GGG 48 Met Trp Asp Leu Val Leu Ser He Ala Leu Ser Val Gly 1 5 10 TGC ACT GGT GCC GTG CCC CTC ATC CAG TCT CGG ATT GTG GGA GGC TGG 96 Cys Thr Gly Ala Val Pro Leu He Gin Ser Arg He Val Gly Gly Trp 15 20 25 GAG TGT GAG AAG CAT TCC CAA CCC TGG CAG GTG GCT GTG TAC AGT CAT 144 Glu Cys Glu Lys His Ser Gin Pro Trp Gin Val Ala Val Tyr Ser His 30 35 40 45 GGA TGG GCA CAC TGT GGG GGT GTC CTG GTG CAC CCC CAG TGG GTG CTC 192 Gly Trp Ala His Cys Gly Gly Val Leu Val His Pro Gin Trp Val Leu 50 55 60 ACA GCT GCC CAT TGC CTA AAG AAG AAT AGC CAG GTC TGG CTG GGT CGG 240 Thr Ala Ala His Cys Leu Lys Lys Asn Ser Gin Val Trp Leu Gly Arg 65 70 75 CAC AAC CTG TTT GAG CCT GAA GAC ACA GGC CAG AGG GTC CCT GTC AGC 288 His Asn Leu Phe Glu Pro Glu Asp Thr Gly Gin Arg Val Pro Val Ser 80 85 90 CAC AGC TTC CCA CAC CCG CTC TAC AAT ATG AGC CTT CTG AAG CAT CAA 336 His Ser Phe Pro His Pro Leu Tyr Asn Met Ser Leu Leu Lys His Gin 95 100 105 AGC CTT AGA CCA GAT GAA GAC TCC AGC CAT GAC CTC ATG CTG CTC CGC 384 Ser Leu Arg Pro Asp Glu Asp Ser Ser His Asp Leu Met Leu Leu Arg 110 115 120 125 CTG TCA GAG CCT GCC AAG ATC ACA GAT GTT GTG AAG GTC CTG GGC CTG 432 Leu Ser Glu Pro Ala Lys He Thr Asp Val Val Lys Val Leu Gly Leu 130 135 140 CCC ACC CAG GAG CCA GCA CTG GGG ACC ACC TGC TAC GCC TCA GGC TGG 480 Pro Thr Gin Glu Pro Ala Leu Gly Thr Thr Cys Tyr Ala Ser Gly Trp 145 150 155 GGC AGC ATC GAA CCA GAG GAG TTC TTG CGC CCC AGG AGT CTT CAG TGT 528 Gly Ser He Glu Pro Glu Glu Phe Leu Arg Pro Arg Ser Leu Gin Cys 160 165 170 GTG AGC CTC CAT CTC CTG TCC AAT GAC ATG TGT GCT AGA GCT TAC TCT 576 Val Ser Leu His Leu Leu Ser Asn Asp Met Cys Ala Arg Ala Tyr Ser 175 180 185 GAG AAG GTG ACA GAG TTC ATG TTG TGT GCT GGG CTC TGG ACA GGT GGT 624 Glu Lys Val Thr Glu Phe Met Leu Cys Ala Gly Leu Trp Thr Gly Gly 190 195 200 205 AAA GAC ACT TGT GGG GGT GAT TCT GGG GGT CCA CTT GTC TGT AAT GGT 672 Lys Asp Thr Cys Gly Gly Asp Ser Gly Gly Pro Leu Val Cys Asn Gly 210 215 220 GTG CTT CAA GGT ATC ACA TCA TGG GGC CCT GAG CCA TGT GCC CTG CCT 720 Val Leu Gin Gly He Thr Ser Trp Gly Pro Glu Pro Cys Ala Leu Pro 225 230 235 GAA AAG CCT GTT GTG TAC ACC AAG GTG GTG CAT TAC CGG AAG TGG ATC 768 Glu Lys Pro Val Val Tyr Thr Lys Val Val His Tyr Arg Lys Trp He 240 245 250 AAG GAC ACC ATC GCA GCC AAC CCC TGAGTGCCCC TGTCCCACCC CTACCTCTAG 822 Lys Asp Thr He Ala Ala Asn Pro 255 260 TAAACTGCAG 832 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 261 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: Met Trp Asp Leu Val Leu Ser He Ala Leu Ser Val Gly Cys Thr Gly 1 5 10 15 Ala Val Pro Leu He Gin Ser Arg He Val Gly Gly Trp Glu Cys Glu 20 25 30 Lys His Ser Gin Pro Trp Gin Val Ala Val Tyr Ser His Gly Trp Ala 35 40 45 His Cys Gly Gly Val Leu Val His Pro Gin Trp Val Leu Thr Ala Ala 50 55 60 His Cys Leu Lys Lys Asn Ser Gin Val Trp Leu Gly Arg His Asn Leu 65 70 75 80 Phe Glu Pro Glu Asp Thr Gly Gin Arg Val Pro Val Ser His Ser Phe 85 90 95 Pro His Pro Leu Tyr Asn Met Ser Leu Leu Lys His Gin Ser Leu Arg 100 105 110 Pro Asp Glu Asp Ser Ser His Asp Leu Met Leu Leu Arg Leu Ser Glu 115 120 125 Pro Ala Lys He Thr Asp Val Val Lys Val Leu Gly Leu Pro Thr Gin 130 135 140 Glu Pro Ala Leu Gly Thr Thr Cys Tyr Ala Ser Gly Trp Gly Ser He 145 150 155 160 Glu Pro Glu Glu Phe Leu Arg Pro Arg Ser Leu Gin Cys Val Ser Leu 165 170 175 His Leu Leu Ser Asn Asp Met Cys Ala Arg Ala Tyr Ser Glu Lys Val 180 185 190 Thr Glu Phe Met Leu Cys Ala Gly Leu Trp Thr Gly Gly Lys Asp Thr 195 200 205 Cys Gly Gly Asp Ser Gly Gly Pro Leu Val Cys Asn Gly Val Leu Gin 210 215 220 Gly He Thr Ser Trp Gly Pro Glu Pro Cys Ala Leu Pro Glu Lys Pro 225 230 235 240 Val Val Tyr Thr Lys Val Val His Tyr Arg Lys Trp He Lys Asp Thr 245 250 255 He Ala Ala Asn Pro 260 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 15: Val Pro Leu He Gin Ser Arg He Val Gly Gly Trp Glu 1 5 10 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: Cys Ala Leu Pro Glu Lys Pro Ala Val Tyr Thr Lys Val Val His Tyr Arg Lys 1 5 10 15 Trp He Lys Asp Thr He Ala Ala Asn 20 25 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: He Val Gly Gly Trp Glu Cys Glu Lys 1 5 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: Asp Arg Val Tyr He His Pro Phe His Leu Leu Val Tyr Ser 1 5 10 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( ii ) MOLECULE TYPE : peptide (xi ) SEQUENCE DESCRIPTION : SEQ ID NO : 19 : Val Pro Leu He Gin Ser Arg He Val Gly Gly Trp Glu Cys 1 5 10 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: His Cys Leu Lys Lys Asn Ser Gin Val Trp Leu Gly Arg His Asn Leu 1 5 10 15 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: Phe Val Asn Gin His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys 1 5 10 15 Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Ala 20 25 30 (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: Cys Ser Gly Lys He Val He Ala Arg Tyr Gly Lys Val Phe Arg Gly Asn Lys 1 5 10 15 Applicants or agents file International application N reference number 545.0O3WO1 1 63 INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 136M) -America Type Culture Cv.lk.tion 11301 Par-lawn DOT. • Rock.llle, MD l β lSJ USA • T.lephon.: (301)231-5520 T.l«x: I9.-05S ATCCNORTH • FAX: 301-7711-25-7 64 BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE Mayo Clinic 200 First Street SW Rochester, MN 55S05 Deposited on Behalf of: Charles Young, Ph.D., Mayo Clinic Identification Reference by Depositor: ATCC Designation Eschenchia coli HEM 01 , pphK2/pVL1393 69614 The deposit was accompanied by: a scientific description _X_ a proposed taxonomic description indicated above. The deposit was received May 2, 1994 by this International Depository Authority and has been accepted. AT YOUR REQUEST: X We will not inform you of requests for the strain. The strain will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strain. If the culture should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace it with living culture of the same. The strain will be maintained for a period of at least 30 years after the date of deposit, and for a period of at least five years after the most recent request for a sample. The United States and many other countries are signatory to the Budapest Treaty. The viability of the culture cited above was tested May 4, 1 994. On that date, the culture was viable. International Depository Authority: American Type Culture Collection, Roc ville, Md. 20852 USA Signature of person having authority to represent ATCC: CΛΛ , Date: May 4, 1994 Bobbie A. Brandon, Head, ATCC Patent Deposito cc: Warren Woessner *' Form BP4/9

Claims: WHAT IS CLAIMED IS: 1. A diagnostic method comprising: (a) contacting an amount of purified antibodies which specifically bind to phK2 or hK2 with a sample of physiological fluid obtained from a human, wherein said fluid comprises phK2 or hK2, for a sufficient time to allow the formation of binary complexes between at least a portion of said antibodies and a portion of said phK2 or hK2, wherein said antibodies do not significantly react with hK3 ; and (b) determining the amount of one or both of said complexes in said sample and correlating the amount of one or both of said complexes to the presence or absence of prostate cancer in said human. 2. The method of claim 1 wherein the relative amount of one or both of said complexes is compared to a value representative of the amount of one or both of said complexes from a human not at risk of, or afflicted with, prostate cancer. 3. The method of claim 1 wherein steps (a) and (b) are repeated at intervals to monitor the progression of prostate cancer in said human. 4. The method of claim 1 wherein in step (a) the antibodies specifically bind to phK2 and do not bind to hK3 or hK2. 5. The method of claim 1 wherein in step (a) the antibodies specifically bind to phK2 and to hK2 but not to hK3. 6. The method of claim 1 wherein in step (b) the complexes are reacted with an amount of antibodies which specifically bind to phK2 or to hK2 but not hK3, wherein said antibodies comprise a detectable label or bind to a detectable label, to form a detectable ternary complex. 7. A diagnostic method comprising: determining the amount of hK2 polypeptide which is bound to plasma proteins from a sample of human physiological fluid and correlating the amount of said bound polypeptide to the presence or absence of prostate cancer in said human. 8. The method of claim 7 wherein the relative amount of said bound hK2 polypeptide is compared to a value representative of an amount of bound hK2 from a human not at risk of, or afflicted with, prostate cancer. 9. The method of claim 7 wherein the bound hK2 polypeptide is separated from unbound hK2 polypeptide prior to determining the amount of bound hK2 polypeptide. 10. A method to detect hK2 complex formation with plasma proteins, comprising: determining in a sample the amount of hK2 polypeptide which is bound to plasma protein relative to the total amount of hK2 polypeptide. 1 1. A method to detect hK2 complex formation with plasma proteins, comprising: determining in a sample the amount of hK2 polypeptide which is bound to plasma protein relative to the amount of hK2 polypeptide which is not bound to plasma protein. 12. The method of claim 10 or 11 wherein the bound hK2 polypeptides is separated from the unbound hK2 polypeptide prior to determining the amount of bound hK2 polypeptide. 13. The method of claim 7, 10 or 1 1 wherein the bound hK2 polypeptide is reacted with an amount of antibodies which specifically bind to hK2 polypeptides but not to hK3 polypeptides. 14. The method of claim 7, 10 or 1 1 wherein the sample is reacted with an amount of antibodies which specifically bind to hK2 polypeptides but not to hK3 polypeptides. 15. The method of claim 13 wherein the antibodies comprise a detectable label or bind to a detectable label, to form a detectable ternary complex. 16. The method of claim 14 wherein the antibodies comprise a detectable label or bind to a detectable label, to form a detectable ternary complex. 17. The method of claim 7, 10 or 1 1 wherein the plasma protein is anti- chymotrypsin. 18. The method of claim 7, 10 or 11 wherein the plasma protein is α2- macroglobulin. 19. The method of claim 7, 10 or 11 wherein the sample is reacted with an amount of purified antibodies which specifically bind to hK2 which is bound to anti-chymotrypsin. 20. The method of claim 19 wherein the antibodies comprise a detectable label or bind to a detectable label, to form a detectable ternary complex. 21. The method of claim 7, 10 or 1 1 wherein the sample is reacted with an amount of purified antibodies which specifically bind to anti- chymotrypsin. 22. The method of claim 21 wherein the antibodies comprise a detectable label or bind to a detectable label, to form a detectable ternary complex. 23. A purified antibody that specifically binds an hK2 polypeptide and which does not bind to hK3, wherein the antibody also binds to hK2 which is bound to a plasma protein. 24. The antibody of claim 23 wherein the plasma protein is anti- chymotrypsin. 25. A diagnostic kit for detecting or determining phK2 or hK2 which comprises packaging, containing, separately packaged: (a) a solid phase which binds a capture antibody; and (b) a known amount of a detection antibody, wherein the detection antibody specifically binds to phK2 or to hK2 and not to hK3. 26. A diagnostic kit for detecting or determining phK2 which comprises packaging, containing, separately packaged: (a) a solid phase which binds a capture antibody; and (b) a known amount of a detection antibody, wherein the detection antibody specifically binds the pro form of hK2 and not hK3 or hK2. 27. A diagnostic kit for detecting or determining phK.2 or hK2 which comprises packaging, containing, separately packaged: (a) a solid phase which binds a capture antibody; and (b) a known amount of the capture antibody, wherein the capture antibody specifically binds to phK2 or to hK2 and not to hK3. 28. The kit of claim 25 or 26 further comprising a known amount of the capture antibody, wherein the capture antibody specifically binds to at least the pro form of hK2 and not hK3. 29. The kit of claim 25 or 26 wherein the detection antibody is detectabiy labeled or binds to a detectable label. 30. The kit of claim 27 further comprising a detection antibody which is detectabiy labeled or binds to a detectable label. 31. A method of detecting hK2 in vitro, comprising: (a) contacting a sample comprising an amount of an hK2 polypeptide with an amount of a peptide substrate for hK2 for a sufficient time to allow cleavage of the peptide substrate by the hK2 polypeptide to yield subunits of the peptide substrate, wherein the peptide substrate comprises contiguous amino acid residues which form a site to which the hK2 polypeptide binds; and (b) detecting or determining the presence or amount of the subunits of the peptide substrate. 32. The method of claim 31 wherein the peptide substrate is a synthetic peptide substrate. 33. A method for detecting or determining hK2, which is not bound to a plasma protein, in a sample of a human physiological fluid containing hK2 which comprises: (a) contacting an amount of purified antibodies which specifically bind to hK2 with the sample to be tested for a sufficient time to allow the formation of binary complexes between at least a portion of said antibodies and a portion of said hK2, wherein said antibodies do not significantly react with hK3, and wherein said antibodies do not significantly react with hK2 which is bound to a plasma protein; and (b) detecting or determining the presence or amount of hK2 complexed with said antibodies. 34. The method of claim 33 wherein in step (b) the hK2 complexes are reacted with an amount of antibodies which bind specifically to hK2 and do not bind to hK3, wherein said antibodies comprise a detectable label or bind to a detectable label, to form a detectable ternary complex. 35. The method of claim 33 wherein the antibodies are attached to a solid surface prior to contact with the sample. 36. The method of claim 33 wherein the plasma protein is anti-chymotrypsin.

Inventors: GRAUER LANA, KLEE GEORGE G, MIKOLAJCZYK STEPHEN D, SAEDI MUHAMMAD SAEED, TINDALL DONALD J, YOUNG CHARLES Y F, GRAUER, LANA, KLEE, GEORGE, G., MIKOLAJCZYK, STEPHEN, D., SAEDI, MUHAMMAD, SAEED, TINDALL, DONALD, J., YOUNG, CHARLES, Y., F.
Applicants: HYBRITECH INC, MAYO FOUNDATION, HYBRITECH INCORPORATED, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Application year: 1997
Main classification: G01N33
IPC codes: C07K14, C07K16, C12N5, C12N9, C12N15, C12P21, C12R1, G01N33